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 The longitudinal muscle layer in gut is the functional 
opponent to the circular muscle layer during the peristalsis 
reflex.  Differences in innervation of the layers allow for the 
contraction of one layer that corresponds with the simultaneous 
relaxation of the other, enabling the passage of gut contents in 
a controlled fashion.  Differences in development have given the 
cells of the two layers differences in receptor populations, 
 membrane lipid handling, and calcium handling 
profiles/behaviors.  The kinase signaling differences between 
the two layers is not as well characterized.  Upon activation of 
cells from the circular muscle layer, it is known that Rho 
kinase and ERK1/2 promote contraction, while CaMKK/AMPK and 
CaMKII perform inhibitory/self-inhibitory roles.  Such behaviors 
are poorly understood in the longitudinal muscle layer. 
 In longitudinal muscle strips, we measured muscarinic 
receptor-mediated contraction following incubation with kinase 
inhibitors.  Upon comparison to control, contributions of Rho 
Kinase and ERK1/2 were similar to those seen in circular muscle.  
Inhibition of both of these enzymes leads to diminished 
contraction.  However, CaMKK/AMPK and CaMKII have effects in 
longitudinal muscle opposite to their regulation in circular 
muscle – their inhibition also diminishes the contractile 
response.  These contractile data from strips were supported by 
immunokinase assay measurements of MLCK activity from strip 
homogenates with and without kinase inhibition.  Therefore, we 
suggest that the activities of CaMKK/AMPK and CaMKII in 
longitudinal muscle are indeed different from their regulatory 
roles in circular muscle, perhaps a consequence of the different 
calcium handling modalities of the two muscle types. 
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  INTRODUCTION 
Function of Gut 
Simply, the gut is a muscular tube that allows for the intake, 
processing, absorption, and elimination of solid and liquid 
nutrients.  The coordination of these roles involves the varied 
chemical and mechanical abilities of the gut.  These abilities 
in turn require numerous control mechanisms to maintain proper 
function. 
Gut as Agent of digestion/absorption/defense 
The primary role of the gut is acquisition of necessary 
nutrients for the maintenance of overall structural integrity 
and energy supply, fueling the metabolic processes of the body.  
As food and drink are ingested, regions of the gut play specific 
roles in the mechanical and chemical breakdown of food 
(digestion).  Mechanically, the muscular tube can collapse upon 
its contents, physically compressing them to render the contents 
into smaller pieces, leading to a suspension (or emulsion) of 
the various ingested substances.  Different types of mechanical 
activity ensure both this disassembly of ingesta and the 
coordinated movement of ingesta through the gut, where a variety 
of place-specific chemical processes can occur [1].  
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Chemically, the gut releases agents into its lumen, where 
mixing with the contents leads to chemical reactions that reduce 
large polymer molecules (e.g. starches, proteins, triglycerides) 
into smaller constitutive pieces (e.g. sugars, peptides, fatty 
acids). This chemistry facilitates the absorption of these 
ingested materials by non-muscular components.  The epithelium 
facing the lumen possesses membrane bound enzymes that offer 
final digestion of proteins and carbohydrates and the absorption 
into the cells of the epithelium.  Lipid digestion products also 
enter the epithelial cells by diffusion.  After entry into the 
cells, the absorbed nutrients enter the blood stream as gut 
tissue is highly served by both the circulatory and lymphatic 
systems.  Digestion products that remain unabsorbed continue 
passage through the gut for elimination from the organism. 
The gut interior is contiguous with the external environment 
and possesses considerable surface area.  Because of its high 
exposure, the gut has intricate immunological roles and 
abilities to prevent introduction of harmful substances or life 
forms into the body.  These functions are carried out by cells 
or tissues that are distinct from the cells or tissues charged 
with the mechanical and chemical duties already mentioned.  
These cells and tissues offer regulation of gut function, 
including motility, and their roles in maintenance of basic 
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functions is beginning to find appreciation in the 
literature[2].  Under normal conditions, beyond immunological 
threat, the gut itself possesses sensory functions upon its 
exposure to contents of a meal.  Such sensory cells can perhaps 
feed into a control network that manipulates motility, 
secretory, and absorptive behaviors.  Altered behaviors could 
optimize the efficiency of the gut when the contents warrant, or 
prevent inefficiency when stimuli communicate harmful or 
wasteful contents [3, 4]. 
Transit of Gut Contents 
The movement of contents through the gut and the mechanical 
treatment of contents while inside the lumen are critical for 
efficient absorption of nutrients.  Two general patterns of gut 
motility accomplish these roles.  Both motility patterns require 
coordinated activity of the two muscular layers of the gut, the 
circular muscle layer and the longitudinal muscle layer.   
The circular muscle layer consists of muscle cells oriented 
around the circumference of the gut lumen, forming adjacent 
rings of muscle that extend throughout the gut.  Upon local 
activation of these cells, the circular muscle tissue contracts, 
and these muscular rings decrease their diameter and therefore 
the caliber of the gut lumen.  The longitudinal muscle layer is 
comprised of cells oriented along the long axis of the gut, 
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parallel to the overall direction of the movement of contents.  
Upon local activation, the contraction of longitudinal muscle 
causes the gut lumen to increase its diameter in a manner that 
shortens the gut at that location.  Because of their opposing 
actions on the gut lumen, the two muscular layers will not 
normally activate at the same location simultaneously. However, 
when these opposing actions occur at adjacent locations, the 
contents of the lumen can be manipulated in a controlled fashion 
[5]. 
Gut Anatomy 
Gut structure varies along the length of the canal, but 
generally possesses a consistent layered organization.  Outer 
layers provide for structural integrity and muscular activity, 
and inner layers secrete substances into the lumen and have 
mechanisms that allow for the absorption of ingested nutrients.  
In addition, there are neural connections and vascular pathways 
throughout all gut tissue. 
Gross Anatomy 
The innermost layer of the gut is the mucosa, containing both 
the epithelial cells necessary for final digestion and 
assimilation of the ingested material, and the lamina propria, a 
layer of connective tissue with capillaries and lacteals to 
convey absorbed nutrients.  In addition, the mucosal layer 
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possesses glands able to secrete substances into the gut lumen, 
cells with sensory capabilities, and the muscularis mucosae, a 
thin layer of smooth muscle that aids in enhanced contact of the 
epithelium with luminal contents as a result of its contractile 
function.  Outside of the mucosal layer lies the submucosa, 
another layer of connective tissue that possesses connections to 
the vasculature, inflammatory cells, and in some cases, glands. 
The submucosa contains a neural plexus, the submucosal plexus 
which has interconnections within the nervous system of the gut 
(enteric nervous system), as well as connections to the 
autonomic nervous system.  This submucosal plexus is important 
in controlling the secretory functions of the mucosa through 
innervation of the epithelium, and may play a role in the 
coordination of muscularis mucosae and muscularis externa 
activity with secretory activity[6]. 
External to the submucosa is the circular muscle layer, a 
layer of smooth muscle cells oriented circumferentially to the 
central axis of the gut lumen.  When cells in this muscle layer 
contract, the overall effect is the narrowing of the lumen at 
this location.  When properly coordinated, this narrowing of the 
lumen can propel the luminal substances within forward in the 
gut.  This contraction can also mix the contents of the lumen at 
the contraction locale.  Because of its muscular activity, this 
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layer also contains blood vessels and neural connections, but 
does not contain the nerve bodies themselves[7]. Continuing 
outward radially, the adjacent layer contains neurons and 
organized connections among these neurons within the enteric 
nervous system, as well as external connections to the autonomic 
nervous system.  This myenteric plexus plays a chief role in 
controlling the muscular activity of the circular muscle layer 
beneath it, and the longitudinal muscle layer above it[8].  The 
longitudinal muscle layer consists of smooth muscle cells 
oriented in parallel with the long axis of the lumen.  The 
longitudinal muscle layer is substantially thinner than the 
circular muscle layer and varies in its receptor population, 
calcium handling, and signaling chemistry[9].  When longitudinal 
muscle contracts, the lumen of the gut is dilated at the 
contraction site and the gut shortened, in contrast to the 
actions of the circular muscle.  The neural connections provided 
by the myenteric plexuses between the longitudinal and circular 
muscle layers coordinate activity ensuring that longitudinal 
muscle and circular muscle do not simultaneously contract at the 
same location in gut[10, 11]. 
Beyond the longitudinal muscle layer there exists a serous 
membrane, the serosa, which serves as an outer containment 
membrane for the gut tube.  The epithelial cells of this layer 
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secrete a serous fluid to lubricate the outer surfaces of the 
gut.  The layers of the gut are depicted in Figure 1 [12]. 
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Figure 1. Structure of the Gut Wall. Adapted from Furness. 
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Cell Types 
Two cell types dominate the population of gut cells – smooth 
muscle cells and epithelial cells.  The smooth muscle cells, 
located in the circular muscle layer and longitudinal muscle 
layer, are responsible for motility patterns of the gut, both 
the propulsive pattern and the non-propulsive segmentation 
pattern.  Smooth muscle cells also are found in the muscularis 
mucosa layer, aiding in exposure of the epithelial cells with 
the gut contents[6].   
The epithelial cells are critical for the absorption of 
nutrients for the luminal contents.  Epithelial cells also 
possess enzymes necessary for the final digestion of the same.  
Beyond these two dominant cell types, there exist several types 
of enteroendocrine cells that serve sensory/control functions 
through monitoring of gut contents and relaying of hormonal 
signals that may affect overall motility, secretory, and 
absorptive action[4, 13]. 
The presence of immune cells and tissue within the gut is 
extensive, a consequence of exposure of the tremendous surface 
area of gut mucosa to the environment.  As such, the entry into 
the body of most antigens occurs through this epithelial 
barrier.  Defending this barrier from pathogenic invasion, while 
recognizing critical resident flora, requires an immune system 
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distinct from the rest of the body[14].  The gut immune system 
initiates responses that cooperate with the general immune 
system.  The gut is also highly served by lymphatic vessels, 
which play a role in lipid absorption.  Because of the size and 
importance of the gut as an immune organ, it possesses a 
population of immune cells greater than the spleen, skin, and 
lymph nodes combined[2].  
Innervation 
The enteric nervous system (ENS) is contained within the two 
anatomical plexuses, the myenteric and submucosal plexuses.  
These structures provide the motor control for the muscle 
layers, secretory control of the mucosal layers, and control for 
the circuitry offered by a variety of sensory mechanisms.  The 
enteric nervous system can stand alone, performing its duties 
independent of the central nervous system, but is normally 
modulated by inputs from the autonomic nervous system.  
Parasympathetic influences upon the ENS originate in the vagal 
nuclei of the brain stem that synapse upon the ENS plexus of the 
esophagus, stomach, and upper intestine, and also from sacral 
parasympathetic nuclei, synapsing upon the plexuses of the 
colon[15].  Parasympathetic activity promotes overall gut 
function, exciting extant motor and secretory pathways.  
Sympathetic activity incident on the gut travels from 
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prevertebral ganglia onto the ENS plexuses.  Such activity 
reduces the actions of the ENS overall, slowing motility and 
secretion.  Sympathetic activity also excites sphincteric 
muscle, preventing organized movement of ingesta through the 
gut[16]. 
As in the central nervous system, the ENS consists of not only 
neurons of various types, but also glial cells that protect and 
maintain the intricate networks of neurons, as well as providing 
modulatory input to neurons of all types.  Complicated 
interconnections of motor and sensory neurons and interneurons 
allow for local control of the sophisticated motor behaviors of 
the gut.  As mentioned, circular muscle contraction must occur 
orad to gut contents (with longitudinal relaxation), and 
circular muscle relaxation caudad to the contents (with 
longitudinal contraction).  Differences in the innervation and 
functions of the circular and longitudinal muscle layers allow 
for this coordination.  
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ICCs/Fibroblast-like cells 
In addition to the connections displayed in the above diagram, 
other cells participate in the shaping of electrical activity.  
The interstitial cells of Cajal (ICC) are neuron-like 
interstitial cells located through the gut.  These cells are 
capable of depolarizing themselves to threshold potential and 
initiating depolarization in surrounding gut muscular tissue.  
The mechanism of their self-depolarization, involving 
intracellular Ca stores and mitochondrial Ca uptake is 
inherently rhythmic, and this rhythmic depolarization is seen 
within the gut musculature that the ICCs influence.  Beyond the 
basic rhythms which are specific to specific gut regions, the 
overall excitability of ICCs can be affected by 
stretch/distention, furthering their contribution to motility, 
as increased frequency of firing promotes both segmentation and 
peristaltic behaviors[17, 18].  Microscopic studies using 
electrically sensitive dyes show that the ICCs may play a role 
in the electrical coupling of the longitudinal and circular 
muscle layer.  This connection is specialized to promote 
coordination without destroying the intrinsic electrical 
identity of the two layers [19, 20].  Another cell type, the 
fibroblast-like cell, appears to co-exist with the ICCs in the 
plexus and muscle layers.  They possess great similarity with 
ICCs, but are reported to be distinguishable via microscopy.  
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These cells are in close proximity to terminals of enteric 
neurons, ICCs, and smooth muscle cells.  Their high current 
densities and apparent gap junction formation with SMC loosely 
suggest that fibroblast-like cells may be involved in a 
modulation role in transmission to and perhaps between the 
muscle layers [21-23].  These results, however, remain highly 
controversial.  
Innervation of Circular and Longitudinal Muscle 
From the neural plexus, processes travel to the muscle layers.  
However, the population of nerves that are efferent to the 
longitudinal muscle layer and the circular muscle layer are 
different in type and quantity.  The motor neurons incident upon 
longitudinal muscle are overwhelmingly excitatory and the vast 
majority of these excitatory neurons contain acetylcholine as a 
neurotransmitter.  Approximately half of these neurons can also 
possess excitatory peptide neurotransmitters, such as the 
tachykinins substance P and neurokinin A[24].   
The lack of a robust population of neurons with inhibitory 
neurotransmitters suggests that inhibition of longitudinal 
muscle is mediated through the control of these existing 
excitatory pathways.  The interneurons that modulate the 
excitatory motor neurons of longitudinal muscle possess 
receptors for typically inhibitory neurotransmitters, such as 
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vasoactive intestinal peptide (VIP) and nitric oxide (NO)[25].  
However, these interneurons excite upon exposure to these 
typical inhibitory agents, and stimulate the release of Ach and 
tachykinins from the downstream motor neurons.  Whereas VIP and 
NO would promote relaxation if directly incident upon muscle 
cells, when incident upon interneurons, contraction is fostered.  
It is thought that these interneurons, specific to longitudinal 
muscle, contribute to the coordinated inverse behaviors of 
circular and longitudinal muscle at the specific site of gut 
activity.  
In circular muscle, a more direct, and yet more involved, 
scheme exists.  The muscle tissue itself is densely innervated 
with both excitatory and inhibitory neurons.  Inhibition of 
circular muscle cells can be elicited by direct neuronal release 
of inhibitory neurotransmitters, whereas a specialized 
interneuron is necessary for the majority of longitudinal muscle 
inhibition.  The receptor population in circular muscle is 
richer in variety and number.  Circular muscle cells possess 
receptors that longitudinal muscle does not, including opioid 
receptors, somatostatin receptors, and neuropeptide Y2 and Y4 
receptors [26-28].  No receptors have been identified that exist 
in longitudinal muscle cells that do not exist in circular 
muscle cells.  Circular muscle can be signaled to contract or 
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relax by a variety of neurotransmitters and circulating agents, 
both peptide and non-peptide in nature.  The control of 
contraction of longitudinal muscle is primarily cholinergic, and 
the control of relaxation in longitudinal muscle is responsible 
to a unique subset of myenteric interneurons which do not 
innervate circular muscle. 
Muscle Contraction 
Muscle activity is driven by the interaction of the proteins 
actin and myosin.  Actin maintains two primary roles in the 
cell, forming both the microfilaments that are critical to 
cytoskeletal structure and the thin filaments in muscle cells 
that provide structure against which the motor protein myosin 
can exert force.  The alpha isoform of actin is the actin 
associated with muscular contraction, whereas the beta and gamma 
isoforms of actin play more important roles in the cytoskeletal 
arrangement[29].  There are several classes of myosin proteins, 
most playing a role in a form of movement, ranging from muscular 
contraction to vesicular transport.  Myosin class II is the 
useful form in muscle, interacting with actin to generate 
force[30].   
Myosin itself is composed of several “chains”, domains of this 
very large protein.  The heavy chains are important in muscle 
contraction, and the light chains important in structure and 
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regulation of the activity of the heavy chains.  The interaction 
of actin and myosin facilitates the inherent ATPase activity of 
the heavy chains of myosin.  Regulation of myosin activity and 
muscle contraction is accomplished by either the regulation of 
the association of actin with myosin or by direct manipulation 
of the catalytic activity of the myosin protein.  The three 
general types of muscle - skeletal, cardiac, and smooth muscle 
each possess differing mechanisms to achieve this 
regulation[31].  However, all mechanisms involve manipulation of 
intracellular levels of free calcium which precede any actions 
of actin and myosin, and all mechanisms involve specific 
proteins that interact directly with either actin or myosin. 
Skeletal 
In skeletal muscle, a nerve impulse is transmitted to a muscle 
fiber by means of the neuromuscular junction.  The action 
potential travels down the sarcolemmal membrane and into the T-
tubules that penetrate into the body of the muscle fiber.  
Dihydropyridine receptors (voltage-gated calcium channels) are 
activated by the depolarization of the action potential upstroke 
and are electrically coupled to the ryanodine receptors on the 
sarcoplasmic reticulum.  Ryanodine receptor activation leads to 
release of calcium from the sarcoplasmic reticulum, and 
intracellular calcium is elevated.  This free calcium binds to 
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the protein troponin, which is in a protein complex with 
tropomyosin.  In low calcium (relaxed) state, the tropomyosin 
within this complex is positioned in a manner that prevents the 
binding of actin and myosin, preventing contraction.  When 
calcium is bound to troponin, however, the troponin-tropomyosin 
complex undergoes a conformational change that removes the 
steric inhibition of actin by tropomyosin, exposing the active 
sites on actin, and permitting actin-myosin interactions.  The 
termination of contraction occurs as the intracellular calcium 
is reduced through the activity of Ca
2+
 ATPases on the 
sarcoplasmic reticular membrane. Unbound troponin reinstates the 
inhibition of actin sites by tropomyosin. 
Cardiac 
Cardiac muscle contraction is similar to skeletal muscle in 
the manner of troponin-tropomyosin-actin interactions.  The 
mechanism that leads to the increase of intracellular free 
calcium that enables these reactions is profoundly different.  
An action potential on the membrane of a cardiomyocyte is not of 
neural origin, but from specialized muscle cells at an alternate 
location in the heart.  The depolarization that led to calcium 
channel activation (and ryanodine receptor activation) in 
skeletal muscle leads to actual calcium entry through similar 
channels in heart.  This calcium entry triggers a large release 
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of calcium from sarcoplasmic reticular stores (Ca-induced Ca-
release), and this sarcoplasmic calcium is responsible for 
troponin binding and the removal of inhibition from actin.  The 
contraction of cardiac muscle is dependent upon the entry of 
extracellular calcium, and the strength of contraction is a 
consequence of the amount of calcium influx and its 
modulation/activation of the ryanodine receptors[32].   
Relaxation is similar, involving the uptake of calcium into and 
its sequestration in the cardiac sarcoplasmic reticulum.  
Smooth 
Smooth muscle contraction has few similarities to the 
excitation-contraction coupling mechanisms in striated muscle.  
Ultimately, contraction is permitted when the regulatory light 
chains of myosin are appropriately phosphorylated.  There is no 
steric interference of the actin and myosin filaments as in 
cardiac and skeletal muscle; troponin is absent in smooth 
muscle, but the thin filaments protein calponin and caldesmon 
have been implicated in similar regulatory roles[33].  
The phosphorylation of the myosin regulatory light chain at a 
serine residue at position 19 is sufficient to cause cross-
bridge formation and cycling, ATP hydrolysis, and muscle 
contraction[34].  Phosphorylation of the regulatory light chain 
in striated muscle does occur, but it is neither sufficient nor 
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necessary for contraction as in smooth muscle.  Such 
phosphorylation in striated muscle, will, however, increase 
force production and speed of contractions[35].   
Smooth muscle has a more dynamic control mechanism than 
striated muscle, as the phosphorylation level of myosin is 
affected by the action of scores of kinases and phosphatases. 
Furthermore, other protein targets exist within smooth muscle 
that can shape the forces developed by the actin-myosin 
interaction dynamics, independent of the myosin phosphorylation 
level.  Investigation of those other mechanisms in general 
smooth muscle and the differences among smooth muscle types are 
the ultimate goal and drive of this study. 
Regulation of smooth muscle contraction 
As stated, the contraction of smooth muscle is driven by the 
control of the phosphorylation level of the 20 kDa regulatory 
light chain of myosin II (MLC20). Membrane receptor activation 
leads to the initiation of second messenger signaling cascades, 
and, ultimately, an increase in intracellular calcium.  The 
calcium binding protein calmodulin complexes with the sudden 
increase in intracellular calcium, and a host of Ca
2+
/calmodulin 
dependent processes are launched.  Of primary interest is the 
Ca
2+
/calmodulin-dependent enzyme myosin light chain kinase 
(MLCK), a dedicated protein kinase of which MLC20 is its only 
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substrate[35].  Phosphorylation levels of MLC20 rise and the 
uninhibited actin/myosin interactions initiate contraction.  
Phosphorylation levels of MLC20 can remain high even as the 
initial Ca2+ transient diminishes, as MLC20 is targeted by kinase 
other than MLCK.  In addition, maintained phosphorylation levels 
and contractile force can be achieved through inhibition of 
myosin light chain phosphatase (MLCP), an enzyme dedicated to 
the dephosphorylation of MLC20. Ultimately, relaxation occurs as 
the phosphatase activity predominates and phosphorylation levels 
of MLC20 fall, reducing the interaction and enzymatic activities 
of actin/myosin[36]. 
Receptors/Membrane-Mediated Processes 
A large variety of receptor types enable a wider variety of 
chemical agents to initiate or modulate smooth muscle 
contraction.  These agents via membrane receptor-mediated 
processes will affect muscle tone through either the 
manipulation of calcium levels (and the Ca
2+
-dependent processes 
MLCK and MLCP), the activation of enzymes outside of the 
standard Ca
2+
-dependent pathways that affect MLC20 phosphorylation 
levels (critical for sustained contraction and relaxation), or 
through the manipulation of the motor proteins themselves 
(altering their affinities for each other or for their assigned 
enzyme effectors)[37].  The enteric nervous system is capable of 
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generating numerous excitatory agents, specific to location, 
motility patterns, and in response to perceived stimuli[38].  
The smooth muscle cells themselves may release agents that can 
elicit local responses, and endocrine agents may bring 
modulation through the general circulation[39].   
Ligands for membrane receptors in gut can be classic non-
peptide neurotransmitters (acetylcholine, dopamine), peptide 
transmitters (somatostatin, vasoactive intestinal peptide), 
peptide hormones (cholecystokinin), or atypical ligands with 
plant-based origins that arrive by ingestion and diffusion to 
the muscle layers[3, 13, 27, 40-43].  Receptor profiles for 
smooth muscle vary among types and even vary within the same 
type at different locations.  Also, identical ligand-receptor 
pairs can elicit differing effects in alternative locations of 
smooth muscle [40, 44, 45].  Most receptors responsible for 
contraction in smooth muscle are coupled to transmembrane G-
proteins, although receptor tyrosine kinase pathways are 
important to growth factor-induced contraction [46, 47].  These 
G-proteins then activate second messengers or directly activate 
specific kinase cascades in the cytosol.  The G-proteins, 
associated second messengers, and kinase cascades are often 
specific to smooth muscle type and function, and may differ 
within the same organ system[45]. 
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Calcium 
The elevation of intracellular calcium is physiologically 
necessary for the initiation of contraction in smooth muscle.  
The primary source for this calcium is the sarcoplasmic 
reticulum of the smooth muscle cell.  Within the SR of smooth 
muscle cells, calcium is primarily bound to the sequestering 
protein calreticulin, and not calsequestrin as in striated 
muscle [48, 49].  Preceding smooth muscle contraction, receptors 
on the SR membrane must be activated so that stored calcium may 
be released into the cytosol.  Here, differences exist between 
smooth muscle types.  In circular smooth muscle of the gut, IP3 
receptors exist on the SR membrane and as levels of the second 
messenger rise, these receptors are activated, and calcium 
release channels open.  In longitudinal muscle of the gut, IP3 
receptors are absent from the SR – external calcium entry is the 
signal to ryanodine receptors for SR calcium release[50].  This 
mechanism of Ca
2+
-induced Ca
2+
 release bears strong resemblance to 
cardiac muscle excitation-contraction coupling, and is specific 
to longitudinal gut smooth muscle.   
The entry of calcium from the extracellular space is another 
mechanism of control.  In longitudinal muscle, this entry is 
coupled to the calcium release from the SR that permits 
contraction.  In both circular and longitudinal muscle, the 
entry of calcium is an important component of the electrical 
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excitability of the muscle.  In both gut muscle types, the 
voltage-dependent calcium channel (VDCC) CaV1.2 is expressed[51].  
Upon depolarization of the sarcolemmal membrane by agonist-
induced inward currents (or local electrotonic depolarization), 
these channels carry the inward calcium current responsible for 
the action potential upstroke[52].  The gating behavior and 
sensitivities of these channels are regulated by various kinases 
upon receptor activation, inflammation, and a host of cellular 
metabolic events [53-55].  The calcium that enters via these 
channels is coupled to SR calcium release in longitudinal 
muscle, as well as the enhancement of kinase pathway activation, 
gene expression, and energy metabolism in both muscle types [56, 
57].  There is also significant interplay between calcium entry 
through these VDCCs and the membrane ion channels (KCa and ClCa) 
responsible for cellular repolarization [58, 59].  
MLCK 
Myosin light chain kinase (MLCK) is a dedicated serine-
threonine kinase that has the 20 kDa regulatory light chain of 
myosin II (MLC20) as its sole substrate.  Upon binding with the 
calcium-calmodulin complex, MLCK phosphorylates MLC20 at serine 
19, permitting the actin-myosin interaction that allow for 
smooth muscle contraction.  Also, phosphorylated MLC20 (MLC20-p) 
is involved in other processes related to cytoskeletal 
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manipulation such as motility, apoptosis, and secretion[35].  
Many studies have shown that MLC20 can be phosphorylated by other 
kinases, and this phosphorylation is important during the 
sustained contraction of tonic smooth muscle, but it is the 
phosphorylation of MLC20 by MLCK that is the predominant effector 
of initial contraction[34, 60, 61].  The activity of MLCK itself 
can be affected by its phosphorylation at several site; kinases 
that phosphorylate can increase or decrease MLCK activity, and 
may do so by either altering the rate of enzyme activity or the 
affinity of MLCK for Ca
2+
-calmodulin [62-66]. 
MLCP 
Myosin light chain phosphatase (MLCP) is the opposing enzyme 
to MLCK, removing the phosphate from Serine 19 on MLC20.  It is a 
trimer composed of protein phosphatase 1c-, the myosin 
phosphatase target subunit 1 (MYPT1), and a small 20kDa unit 
M20[67].  The PP1 family of enzymes is expressed widely in 
tissues and is a non-specific serine/threonine phosphatase.  PP1 
enzymes are typically bound to a targeting subunit to direct 
this non-specific enzymatic action here by MYPT1.  MYPT1 targets 
the phosphatase subunit to MLC20, while increasing the 
specificity of PP1c- through a conformational change that occurs 
when bound to MYPT1[68].  The M20 subunit is of unknown 
function. 
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The overall level of MLC20 phosphorylation is closely tied to 
the activity level of these two opposing enzymes, 
notwithstanding the MLCK-independent phosphorylation of MLC20.  
As MLCK activity can be modified by select kinases, MLCP can 
also be reduced in its activity by interaction with two of its 
subunits.  When the subunit MYPT1 is phosphorylated at threonine 
696 (human), the phosphatase subunit can no longer be directed 
properly to its myosin target [69]. Rho kinase was the first 
studied kinase to phosphorylate MYPT1 in this manner, but 
several kinases have been identified as effectors of MYPT1.  
Some phosphorylate in a manner similar to Rho kinase, and others 
target residues that prevent the Rho Kinase-like inhibition[70].  
The wide range of kinases that target MYPT1 invites discussion 
of perhaps a greater role in cellular functions for MLCP[30].  
The phosphatase subunit PP1c- has an endogenous inhibitor, C-
kinase potentiated protein phosphatase-1 inhibitor (CPI-17).  
The phosphorylation of CPI-17 at serine 12 and threonine 38 
enabled its blocking of PP1c- activity and this phosphorylation 
is performed by many of same kinases that phosphorylate MYPT1 
[71-75]. 
Initial/Sustained 
Contraction in some smooth muscles type is biphasic – an 
initial transient contraction of relatively high amplitude, 
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followed by a lowering of tone to a reduced but sustained 
contraction.  Other muscle types maintain moderate levels of 
tone for extended periods of time.  An initial contraction and 
the initial partial decline agree with the transient change in 
intracellular calcium.  Following the release of calcium by any 
specific mechanism, MLCK activity will increase as it binds to 
calcium-calmodulin complexes.  Following the transient increase, 
calcium uptake by the SR reduces intracellular calcium levels to 
pre-contraction values.  Tone in the muscle can still be 
maintained at a lower degree despite a calcium level that would 
not alone develop such tone.  This phenomenon of elevated tone 
with low calcium is termed calcium sensitization [36, 76].   
Two general mechanisms are responsible for sustained tone.  
Calcium sensitization has been studied extensively in 
preparations where calcium levels are held constant.  Studies 
have shown that both MLCK activity may be altered at constant 
calcium and that MLC20 can be phosphorylated by kinases other 
than MLCK at all levels of calcium[44, 61, 77-79].  These Ca
2+
-
independent processes are partially responsible for the enhanced 
tone of the sustained phase of contraction.  MLC20 
phosphorylation levels are also affected by activity of MLCP, 
and inhibition of this phosphatase activity contributes to 
maintained tone.  Both inhibitors of MLCP activity, 
 28 
phosphorylated CPI-17 and MYPT1, have been implicated in the 
sustained phase, either individually or in concert [80-82].  
CPI-17 and MYPT1 are expressed to different degrees across 
smooth muscle types, and this ratio of expression can be 
connected to general phasic (initial and sustained contractile 
behavior) or tonic (extended sustained contractile with no 
initial peak) motility patterns[83].  Many kinases that offer 
Ca-independent phosphorylation of MLC20 (through either enhanced 
MLCK activity or direct phosphorylation) also phosphorylate the 
inhibitors of MLCP[39, 81].  Agonists that cause standard Ca-
dependent increases in MLCK activity may also promote 
phosphatase inhibition through the same or alternate subtypes of 
their receptors [84, 85]. 
  
 29 
Circular Muscle 
Receptors/G-Proteins/Second Messengers 
Circular muscle in gut expresses an extensive array of 
receptors for both neurotransmitters released by the enteric 
nervous system, agents from gut tissue, and agents in the 
circulation.  Muscarinic receptors are in the greatest number, 
with muscarinic type 2 (M2) outnumbering muscarinic type 3 (M3), 
but only M3 is thought to participate directly in 
contraction[86].  A majority of identified receptors operate 
through G-proteins, but receptor tyrosine kinase activity has 
been seen in intestinal muscle with exposure to members of the 
growth factor family[87].  Though these effects can couple 
downstream with cascades that start at G-proteins, they are 
mainly seen during proliferation and may be primarily 
pathophysiological in presence[88]. 
G-protein activation in circular muscle stimulates 
phosphoinositide (PI) hydrolysis by members of the phospholipase 
C (PLC) family.  The beta isoforms predominate in activity with 
PLC-beta1 downstream of M3 activation (via Gq) and PLC-3 
downstream of M2 activation (via Gi)[89].  Activation of M3 is 
critical for contraction, and leads to hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-
trisphosphate (IP3) and diacylglycerol (DAG)[90, 91].  Both IP3 
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and DAG have downstream effects that shape contraction.  G-
proteins activated in circular muscle may also have downstream 
effects of adenylate cyclase, Rho kinase, PI-3 kinase, and other 
members of the phospholipase family[39].  It is, however, M3 
activation leading to IP3 formation that is essential in the 
initial contraction.  Activation of M2 has downstream effects on 
contraction (primarily inhibitory), but mostly operate on a time 
scale beyond the M3/IP3 consequences[84]. 
IP3/SR Ca release 
With agonist-induced IP3 formation via PLC, IP3 receptors 
(IP3R) are activated on the SR of circular muscle.  These 
receptors are SR membrane calcium channels, have high affinity 
for IP3, and are inhibited by heparin[92].  When IP3 binds to 
these receptors, calcium stored in the SR is released into the 
cytosol[93].  This transient increase in intracellular calcium 
causes binding sites on calmodulin to be occupied, and the 
calcium-calmodulin complexes then activate MLCK, initiating 
contraction.  Other calcium dependent enzymes are also activated 
which may modulate the activities of MLCK and MLCP.  The rise in 
intracellular calcium is short-lived, as pumps on the SR 
membrane re-accumulate the released calcium, and with the 
actions of the cell membrane Ca
2+
-ATPases, restore the levels of 
calcium to previous values.  These IP3 receptors/Ca channels are 
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modulated by association with other receptors on the SR 
membrane, protein kinases, and the level of intracellular 
calcium that these channels manipulate.  All these effects can 
shape the kinetics of release, and consequently the effects of 
the calcium transient [58, 94-97]. 
Ca-Independence 
Following the decline of the calcium transient, Ca-independent 
processes allow for a degree of sustained tone to be maintained.  
Ca-independent kinases such as Integrin-Linked Kinase (ILK) and 
Zipper-interacting protein kinase (ZIPK) phosphorylate MLC20 in 
manner similar to the Ca-dependent MLCK [98-100].  MLC20 
phosphorylation levels are also kept at an elevated level by 
inhibition of the myosin phosphatase, either through 
phosphorylation of MYPT1 or CPI-17.  It is not uncommon for 
agents to initiate the Ca
2+
-independent phosphorylation of myosin 
while simultaneously inhibiting the phosphatase, nor it is 
uncommon for pathways to activate both known mediators of 
phosphatase inhibition [74, 75, 81, 82]. 
Relaxation 
Relaxation is fostered when phosphatase activity exceeds 
active MLC20 phosphorylation.  Both protein kinase A (PKA) and 
protein kinase G (PKG) are implicated in the relaxation of 
smooth muscle.  Inhibitory neurotransmitters such as VIP 
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activate Gs proteins, increasing cAMP levels through adenylate 
cyclase stimulation, and leading to increased PKA activity.  PKA 
can target membrane ion channels leading to hyperpolarization, 
phosphorylate upstream molecules to inhibit contractile 
pathways, and directly phosphorylate MYPT1 in a fashion that 
precludes its role as an inhibitor of MLCP [101-103].  Nitric 
oxide (NO), another inhibitory transmitter, can elevate PKG 
activity through stimulation of soluble guanylate cyclase.  
Protein Kinase G has similar targeting as PKA to inhibit 
contraction/promote relaxation, and has been shown definitively 
also to phosphorylate CPI-17 at a site that precludes its 
involvement in MLCP inhibition [72, 104, 105].  Whether PKA 
targets CPI-17 directly to promote relaxation finds conflict in 
the literature [101, 105]. 
Rho Kinase 
Rho-associated kinase (Rho Kinase) is a serine-threonine 
kinase widely expressed in tissues and implicated in a wide 
array of cytoskeletal processes, including cell motility, cell 
proliferation, neurite growth, and apoptosis[106].  Rho Kinase 
is speculated to be a promising target in treatments of 
Alzheimer’s disease, stroke, multiple sclerosis, and pain [107]. 
Its physiological interaction with cytoskeletal structures also 
leads to a role in muscle contraction, and the inhibition of Rho 
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kinase finds clinical uses in treatment of asthma and 
hypertension [108-110]. 
Effects on contraction by Rho kinase mainly involve its 
phosphorylation of the targeting subunit MYPT1, preventing MLCP 
from removing activating phosphates on MLC20 [111].  This role is 
considered critical in the sustained contraction seen in many 
tissue types, and Rho kinase is seen to be expressed to a higher 
level in those tissues that exhibit more tonic contractile 
behavior [112]. However, studies also demonstrate that the pro-
contractile effects of Rho Kinase may be mediated through 
inhibition of NO synthesis, indirect phosphorylation of MLC20 
through activation of Ca
2+
-independent ZIP kinase, and perhaps 
direct phosphorylation of myosin [113-115]. 
ERK1/2 
Extracellular signal-kinase types 1 and 2 (ERK1/2) are common 
and prevalent participants in signaling cascades connected to 
cellular activities of growth, differentiation, survival, and 
metabolism.  A large portion of the downstream effects of ERK1/2 
effect changes in gene expression in response to extracellular 
signals or events [116].  ERK1/2 is also often involved in acute 
effects or responses and its parent pathways are numerous and 
well-described, and its targets of phosphorylation as varied.   
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Effects on smooth muscle activity are easily connected to the 
role of ERK1/2 in cell proliferation, as cytoskeletal 
rearrangement is crucial to mitotic, differentiation, and motile 
behaviors.  Phosphorylation of the putative contractile 
regulators caldesmon and calponin by ERK1/2 enhance contraction 
[54, 117].  ERK1/2 expression is heightened in models of 
inflammatory disease of the gut, which often present with 
hypercontractility [87, 118].  ERK activity is implicated in the 
physiological contraction of gut and vascular smooth muscle [78, 
119].  These effects of ERK1/2 can be mediated by 
phosphorylation of participants in existing contractile pathways 
incident upon MLCK or by direct phosphorylation of MLCK, 
enhancing MLC20 phosphorylation [65, 66, 120]. 
CaMKII 
Calcium-Calmodulin dependent kinase II (CaMKII) is a 
serine/threonine kinase that is expressed widely in excitable 
tissue. Upon binding with calcium-calmodulin (following a 
transient increase in intracellular calcium), CaMKII 
autophosphorylates at threonine 286 and can maintain its 
activity after dissociating from calcium-calmodulin complexes 
[37].  The kinase can modulate membrane channels and engage with 
downstream kinases such as ERK1/2 [121-124].  CaMKII associates 
with motor proteins in cell migration and hypertrophy, and has 
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receptors and transport proteins of the sarcoplasmic reticulum 
as targets [125-128].   
In smooth muscle cells, inhibition of CaMKII can enhance 
contraction, and this effect has been attributed to the effect 
of CaMKII on MLCK [129]  Phosphorylation of MLCK by CaMKII 
reduces the affinity of MLCK for calcium-calmodulin, decreasing 
its phosphorylation of MLC20, and this phosphorylation has been 
specifically blocked by inhibitors of CaMKII [130, 131].  
However, other studies have indicated a possible link to CaMKII 
activity and tone maintenance in vascular smooth muscle [132, 
133].  These conflicting findings, along with the involvement of 
CaMKII with proteins important in calcium handling (ryanodine 
receptors, phospholamban) indicate the role of this enzyme in 
calcium handling could be complex and not constant across 
tissues with different calcium handling characteristics.  
CaMKK/AMPK 
Adenosine Monophosphate Activated Kinase (AMPK) is an 
important regulator of cellular metabolism, involved in 
adaptation of cellular processes to changes in metabolic level 
(AMP:ATP ratio).  As AMP levels rise, enhanced AMPK activity 
causes changes in glucose transport, lipid metabolism, and 
mitochondrial activity [134-136].  Under normal conditions, AMPK 
can be activated through receptor activation via calcium-
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calmodulin kinase kinase (CaMKK), with the beta isoform of CaMKK 
being the most prevalent upstream mediator [137-139].  
Inhibition of CaMKK is closely correlated with AMPK inhibition 
and is the typical path of pharmacological manipulation [139-
141]. 
AMPK also associated with motor proteins.  AMPK interacts with 
actin filaments of the cytoskeleton in osmotic stress models, 
changing their affinity for other cytoskeletal proteins [142].  
And studies have shown that MLCK is a substrate of AMPK, with 
the phosphorylation of MLCK at a site close to the CaMKII 
phosphorylation site, and resulting in a similar reduction in 
affinity for calcium-calmodulin [143].  AMPK can phosphorylate 
fragments of MLC20, but this is not thought to be part of the 
normal activity of AMPK [144]. 
Putative Circular Muscle Model 
Most gut smooth muscle studies are performed upon smooth 
muscle cells or tissue from the circular muscle layer, 
presumably because of its thickness and perceived dominant role 
in gut motility.  Considering the literature regarding kinase 
manipulations of MLCK/MLCP/MLC20, the following model is offered 
(Figure 2).  Not all possible kinases or kinase targets were 
mentioned and are beyond the scope of this study.  This model is 
similar to many found in reviews and texts [39, 145-147]. 
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Figure 2. Putative Model for Circular Muscle Regulation 
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Longitudinal Muscle 
Longitudinal muscle in gut possesses many differences from the 
circular muscle with which it works in opposition.  These 
differences begin during development and lead to a muscle 
phenotype that possesses a different receptor profile, membrane 
lipid handling, and a mechanism of cytoplasmic calcium handling 
more similar to striated cardiac muscle than any other form of 
muscle, smooth or striated. 
Development 
The epithelium of the gut is derived from embryonic endoderm, 
and the muscle from splanchnic mesoderm.  Neural precursor cells 
of ectodermal origin begin to populate the gut almost 
immediately, and their presence enables the mesenchyme to begin 
to differentiate into what would become the circular muscle 
layer [148].  There is debate on the origin of what will become 
the longitudinal layer.  Some believe that longitudinal muscle 
develop from circular muscle cells, others from a common 
precursor that gives rise to both the ICCs and the longitudinal 
muscle layer [149, 150].  Regardless, the development of the 
longitudinal muscle is delayed relative to the circular, as this 
is seen in both mouse model and human embryo [151].  ICCs are 
often characterized by their expression of c-kit, a receptor 
tyrosine kinase, as ICCs and mast cells are the only cells in 
the gut that express c-kit.  Blockade of c-kit signaling in the 
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gut abolishes the development of both the ICCs and the 
longitudinal muscle, intimating that at the very least, ICC 
signaling is necessary for longitudinal muscle development.  The 
possibility the ICCs and longitudinal muscle cells come from the 
same progenitor agrees with this finding [152].  Known 
organogenetic proteins such as Shh, BMP, forkhead, and Wnt are 
suspected to play roles in the radial patterning of the gut, it 
seems that platelet derived growth factor (PDGF) may be the most 
important [153].  Studies report that the cells destined to be 
the longitudinal muscle layer express receptors for PDGF, which 
is released by more internal parts of the gut.  This receptor 
development could be caused by a gradient of these other 
signaling proteins, but the combination of a substantive PDGF 
receptor and appropriate ligand allows for longitudinal muscle 
to differentiate from the c-kit expressing layer [154]. 
Receptors/Phosphoinositides 
As stated earlier, the receptor population of circular muscle 
cells and longitudinal muscle cells are different.  Longitudinal 
muscle lacks receptors for opioids, somatostatin, and 
neuropeptides Y2 and Y4 [27, 28, 42].  This variance in receptor 
population coincides with a lesser degree of innervation that 
longitudinal muscle possesses – the innervating neurons are 
fewer in number, almost completely excitatory, and primarily 
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cholinergic (secondary are the tachykinins).  Circular muscle is 
innervated by excitatory and inhibitory neurons that offer a 
greater variety of ligands to match the receptor variety. 
Muscarinic receptors are common between the two muscle types, 
and M3 activation in both muscle layers leads to activation of 
PLC-1.  Other agonists and the M2 receptors can operate to 
increase PLC-3 via Gi mechanism in both muscle types.  PLC 
then turns upon membrane lipids as substrate for the generation 
of second messengers.  Here, another variation is seen; in 
circular muscle, the primary target of PLC is PIP2, and the 
generated second messenger is IP3.  In longitudinal muscle, the 
primary substrate is PIP and the generated second messenger IP2 
[90, 93]. 
In circular muscle, the IP3 generated from PLC activity is 
the ligand responsible for calcium liberation into the cytosol.  
IP3 receptors on the sarcoplasmic reticulum bind to cytoplasmic 
IP3, opening channels and increasing intracellular calcium, 
enabling the contractile mechanism.  Longitudinal muscle 
generates little IP3, and the sarcoplasmic reticula of 
longitudinal muscle have very few IP3 receptors [50].  Yet, 
contraction occurs in longitudinal muscle despite the signaling 
differences. 
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Calcium Handling 
Longitudinal muscle does not generate IP3 nor does it have IP3 
receptors on its sarcoplasmic reticular membrane.  A 
fundamentally different mechanism is utilized to usher calcium 
release into the cytosol.  The sarcoplasmic reticula of 
longitudinal muscle possess ryanodine receptors, which are 
insensitive to IP3.  These ryanodine receptors exist elsewhere in 
the gut, even in circular muscle, but only in longitudinal 
muscle is their contribution physiologically relevant and 
necessary for contraction [155-157].  Sarcoplasmic reticula with 
high populations of ryanodine receptors resemble a cardiac 
muscle paradigm, and longitudinal muscle also shares with 
cardiac muscle the mechanism by which the release of calcium 
from the SR is regulated.   
Studies with calcium channel blockers have shown that 
contraction in circular muscle is not hindered by removal of 
extracellular calcium or the block of sarcolemmal calcium 
channels.  Eventually, contractions do decline in amplitude, but 
this is a consequence of normal cellular extrusion of calcium.  
Without entry of extracellular calcium, such stores will 
eventually exhaust.  In longitudinal muscle, however, removal of 
extracellular calcium or blockade of calcium entry diminishes 
contractions immediately.  Just as in heart, the entry of 
calcium into the cell is obligatory for the release of calcium 
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from the sarcoplasmic reticulum in longitudinal muscle [158]  
Such release is possible in circular muscle, but the necessary 
concentration to trigger release is very high, and is primarily 
seen in permeabilized cell preparations where such 
concentrations can be realized [50].  Under physiological 
conditions, calcium-induced calcium release is not seen in 
circular muscle. 
The mechanism that modulates calcium entry in longitudinal 
muscle differs from its cardiac counterpart.  In heart, the 
depolarization of the action potential is sufficient to gate 
surface membrane calcium channels, allowing for the calcium 
entry that triggers SR calcium release.  This is not necessary 
for contraction in longitudinal smooth muscle, yet the membrane 
must depolarize before the VDCCs can open.  As an excitable 
tissue, it is reasonable that depolarization could spread 
electrotonically from a distant locale, bringing the membrane to 
threshold for the calcium channels, allowing calcium entry.  But 
agonists can initiate contraction in isolated conditions with no 
external depolarizing effort.  A second messenger must be 
responsible.  The agent was discovered to be arachidonic acid 
(AA), a polyunsaturated fatty acid that can be liberated from 
membrane lipids by phospholipase A2 (PLA2) in the cytosol 
(cytoplasmic PLA2, cPLA2) [159].  AA activates chloride 
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channels, causing the inward current that depolarizes the 
membrane and gates the calcium channels.  Similar experiments in 
circular muscle showed no connection between chloride channels, 
AA, and calcium entry [160].  Further regulation is conveyed by 
cyclic ADP-ribose (cADPR), an endogenous nucleotide known to 
modulate calcium release from ryanodine-sensitive calcium 
stores.  Circulating levels of cADPR can be increased through 
receptor activation and stimulation of ADP-ribosyl cyclase, 
enhancing SR ca efflux.  Circular muscle demonstrated no such 
similar mechanism. 
Rationale 
Given the differences in development, receptor population, 
lipid chemistry, and in particular, calcium handling, it is 
hypothesized that the actions of the kinases known to modulate 
MLC20 phosphorylation in circular muscle may have different 
actions in longitudinal muscle.  Following the model in Figure 
2, and using longitudinal muscle strips from rat colon, changes 
in contractile behavior was measured in the presence and absence 
of inhibitors for Rho Kinase (Y27632), ERK1/2 (PD98059), CaMKII 
(KN-62), and CaMKK/AMPK (STO-609).  Contraction was be elicited 
by carbachol (m2 and m3 activation).  Molecular techniques 
illustrated direct effects of the kinases on MLCK. 
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MATERIALS AND METHODS 
Materials 
Unless otherwise noted, all chemicals were obtained from 
Sigma-Aldrich (St. Louis, MO).  Kinase Inhibitors Y27632 (Rho 
kinase), PD98059 (ERK1/2), STO-609 (CaMKK/AMPK), and KN62 
(CaMKII) were purchased from Calbiochem (La Jolla, CA).  15% 
Tris-HCl Ready Gels and DC Protein Assay Kit were products of 
Bio-Rad (Hercules, CA), Myelin Basic Protein was purchased from 
Upstate Biotechnology (now Millipore, Billerica, MA) and [-
32
P]ATP from Perkin Elmer Life Sciences (Boston, MA).  Antibody 
for MLCK and protein A/G agarose beads are products of Santa 
Cruz Biotechnology (Santa Cruz, CA).   
Sprague-Dawley Rats were purchased from Charles River 
Laboratories (Wilmington, MA) and housed in the animal facility 
of the Division of Animal Resources, Virginia Commonwealth 
University.  All procedures followed guidelines of and were in 
accordance with the Institutional Animal Care and Use Committee 
of Virginia Commonwealth University. 
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Animal Preparation 
Rats were euthanized by CO2 asphyxiation under approved 
protocols.  The colon was dissected out, emptied of contents and 
placed in a warmed (37°C) oxygenated Krebs solution of the 
following composition (in mM): 118 NaCl, 4.75 KCl, 1.19 KH2PO4, 
1.2 MgSO4, 2.54 CaCl2, 25 NaHCO3, 11 mM glucose (pH 7.4).  2-3 cm 
sections of colon were removed and threaded onto a glass rod, 
where the longitudinal muscle/myenteric plexus (LM-MP) was 
removed by radial abrasion with a lab wipe.  The resultant strip 
of muscle was freed of excess fat and mesenteric attachments and 
held in oxygenated Krebs buffer until use for tension recording 
or molecular assay. 
Strip Preparation  
Strips destined for recordings of contractile behavior were 
tied at both ends with surgical silk – on one end a simple loop 
for attachment to a glass hook, the other end to a length of 
silk tied to a brass ring.  The strip was then placed in a 
vertical orientation with the loop secured to a glass hook and 
the brass ring to a Model FT03C Force Transducer (Grass 
Technologies, Quincy, MA).  An organ bath (Radnoti, Monrovia, 
CA) was raised to submerge the strip in 5 mL of continuously 
oxygenated and warmed Krebs solution.  Force recordings were 
amplified by a 15A12 model amplifier (contained within a Model 
15LT Amplifier System), relayed to a PVA-16 Polyview Adaptor 
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Unit (A/D-D/A converter), and displayed/stored by a PC running 
Polyview Version 1.3 (Grass Technologies, Quincy, MA).  Force 
was recorded in grams per the software specifications.  All 
analysis of data traces was performed within the Polyview 
software itself, as exportation of usable raw data was limited 
by software design. 
Strips destined for molecular assay were treated as those 
intended for recordings – time scales for inhibitor incubation 
and agonist exposure were identical.  Following prescribed 
incubation times, tissue strips were submerged in a bath of 
Krebs with 1 M carbachol. After 60 seconds of immersion in 
carbachol/Krebs (corresponding to a normal vigorous response 
seen in strips), strips were flash frozen in liquid nitrogen and 
placed into TPER (Tissue Protein Extraction Reagent, Pierce, 
Rockford, IL) or lysis buffer with composition 50 mM Tris-HCl 
(pH 7.5), 150 mM NaCl. 0.1% SDS, 0.5% sodium deoxycholate, 1% 
NP-40, 10 mM sodium pyrophosphate.  Into either vehicle, a 
protease/phosphatase cocktail (100 g/mL PMSF, 10 g/mL 
leupeptin, 30 mM sodium fluoride and 3 mM sodium vanadate) was 
added at a concentration of 2 L/mL.  Tissue was homogenized and 
solubilized in the above solutions.  Following centrifugation at 
20000 g for 15 min at 4°C, the protein concentration of the 
supernatant was assessed with a DC protein assay kit.  These 
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supernatant lysates were stored at -80°C until needed for 
immunokinase assay. 
Isometric Force Measurement 
Force experiments were conducted in the following manner.  
Following hanging of the strip and submersion in the organ bath, 
strips were subjected to approximately 1 gram of pre-tension via 
the mounting rack-and-pinion.  Strips were allowed to 
equilibrate for no less than 30 minutes before experiments were 
conducted and data collected.  Exposure to inhibitors, blockers, 
and carbachol (sole agonist) occurred within the organ bath.  
Concentrations were appropriate and in agreement with current 
literature and are noted in the results. 
Following an experiment, strip data were reviewed and analyzed 
from within the Polyview software suite.  All experiments were 
designed to compare treatment to control conditions.  Paired t-
tests were conducted in GraphPad (GraphPad Software, La Jolla, 
CA), and significance assumed at P < 0.05. Often in summary, 
treatment conditions were displayed as compared to control, but 
significance relays to the raw data paired t-test.  
Data Analysis 
Contractile data was viewed from several perspectives as to 
the effects of kinase inhibition: changes to basal tone upon 
kinase inhibitor administration, peak contractile amplitude 
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following agonist exposure, and an area under the curve 
measurement to quantify the contraction as viewed during the 
first two minutes of the contraction in an effort to determine 
differences in force development/decay. All numerical values are 
offered as mean ± SEM.   
Basal Tension 
Basal tension was measured as the mean tension during a 3 
minute period following at least 30 min of equilibration 
(control conditions) or 10 min of inhibitor incubation (basal 
recording obtained in interval proceeding carbachol 
administration).  Such measurements were made in multiple strips 
from multiple animals, and paired t-tests conducted to 
demonstrate a significantly appreciable effect. 
Peak Contraction 
Peak contraction (amplitude) was defined to be the greatest 
amplitude of tone above basal during the two minute period 
following agonist administration.  This two minute period is 
taken to begin when tone appreciably elevates from basal value.  
Differing geometries of the shape of the contraction waveform 
allows for this peak measurement to occur at varying time 
indices following carbachol administration.  An example of such 
a measurement (utilizing a constructed model curve) is displayed 
in Figure 3. 
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Figure 3. Peak Amplitude Measurement. 
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Contraction at 1 min and 2 min post exposure 
In strips that developed an early peak that subsided quickly, 
the amplitude of the contraction above basal was also recorded 
at 1 minute and 2 minutes following the initial increase in tone 
due to agonist administration (the beginning of the studied 
interval). An example of such measurements (utilizing 
constructed model curves) is displayed in Figures 4 and 5. 
AUC for first minute and first two minutes of exposure 
The area underneath a curve representing force versus time has 
no physical definition in an isometric contraction.  Energy 
expenditure cannot be quantified without a displacement.  But 
along with the values of the contraction at 1 min and 2 min as 
percentage of peak, these quantities do speak to the development 
and maintenance of the tension, and do help describe the decay 
of the same.  This is a typical method used to describe 
contraction curves in muscle strips.  Examples of these 
measurements: AUC 0-1 min, AUC 1-2 min, and AUC 0-2 min 
(utilizing constructed model curves) are offered in Figures 6-8. 
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Figure 4. Contraction at t = 1 minute. 
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Figure 5. Contraction at t = 2 minutes. 
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Figure 6. Area under the curve, 0-1 minute. 
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Figure 7. Area under the curve, 1-2 minutes. 
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Figure 8. Area under the curve, 0-2 minutes. 
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Kinase Assay 
Activities of MLCK activity were measured by an immunokinase 
assay as performed in earlier studies from the lab [85, 88, 161, 
162].  100 g of protein was transferred from the supernatant of 
prepared tissue sample to a designated tube and 1 μg of MLCK 
goat antibody was added.  At 4°C, this mixture was incubated for 
2 hours.  Protein A/G agarose beads were added to each sample, 
and the mixture again incubated at 4°C overnight.  Following 
centrifugation, supernatants were withdrawn and the 
beads/protein washed with lysis buffer three times. 
The bead/protein pellets were resuspended in kinase buffer 
with composition (in mM): 100 tris-HCl, 1000 KCl, 50 MgCl2, 10 
EDTA, and 1 DTT.  Twenty microliters of this mixture were added 
to a reaction mixture of (in mM): 100 tris-HCl, 1 KCl, 50 MgCl2, 
1 DTT, 1 ATP, and 10 Ci of [-32P]ATP (3000 Ci/mol) with 5 g 
myelin basic protein as kinase target substrate.  This mixture 
was incubated for 15 min at 37°C.  Twenty microliters of this 
mixture (and the accompanying myelin basic protein 
phosphorylated with -32P) was absorbed onto phosphocellulose 
filter paper disks, and free radioactivity washed away by 
repeated immersion in 75 mM H3PO4.  Radioactivity was then 
measured by liquid scintillation, and values expressed as 
counts/minute per microgram of protein. 
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RESULTS 
Sample Traces 
Sample traces are offered to demonstrate the variety of 
contraction waveforms.  Most contractions studied (~75%) possess 
a waveform similar to the top panel of Figure 9 – a sharp rise 
in developed tension, followed by a decrease to a sustained 
level within 60-90 seconds.  Other contractions (~20%) may show 
a rise in tension without appreciable decay, maintaining an 
elevated tone, as in the bottom panel of Figure 9.  Contractions 
that demonstrated little decline following an early peak were 
not utilized in measurements that attempted to quantify the 
decay in tension (t = 1 min, t = 2 min studies). 
In addition, contractions may exhibit phasic activity 
superimposed upon the described waveforms.  An example of such a 
waveforms in displayed in Figure 10.  For waveforms with 
prominent phasic components, contraction values at 1 min and 2 
min were interpolated values.  Area under the curve values were 
utilized as recorded, unless phasicity was extreme enough to 
take the minima of contractions to values below the initial 
baseline tension.  Polyview software would treat such as 
negative areas under the curve and complicate the analysis.  
Such tracings were not utilized for AUC data. 
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Figure 9. Sample traces from main Polyview screen. 
Top Panel: Trace indicative of early peak tension development 
and substantial decay to sustained level.  Trace line enhanced 
for ease of viewing 
Bottom Panel: Trace indicative of little decay following peak 
tension.  Trace line enhanced for ease of viewing. 
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Figure 10. Sample partial trace from Zoom screen of Polyview 
Software suite.   
Trace indicative of strips that exhibit phasic activity 
superimposed upon standard decay.  Zoom feature of Polyview 
automatically filters and smoothes resultant data.  Calculations 
are performed on original raw data. 
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Control Behavior of Strips due to carbachol 
Strips were exposed to carbachol (CCh) at concentrations of 10 
nM, 1 M, and 100 M.  10 nM elicited contraction in strips 
approximately 50% of the time, and data from these responsive 
strips were utilized. 1 M CCh consistently produced robust 
responses, and 100 M CCh reliably produced a maximal response.  
These doses are consistent with similar studies conducted using 
strips [40, 163].  
Circular muscle strips were not viable preparations in this 
study.  Although circular muscle strips can be prepared from 
human tissue reliably, in rat it is apparent that the 
longitudinal muscle layer provides needed integrity to the 
muscle strip – in its absence, circular muscle tears easily 
(along its physiological orientation) when subjected to tension.  
Similar difficulties have been noted in the literature [163, 
164]. 
Contraction Dose response 
The grand mean of control responses by carbachol dose are 
displayed in Figure 11.   Contractile responses were 0.51 ± 0.06 
grams at 10 nM CCh (n=40), 1.00 ± 0.12 grams at 1 M CCh (n=50) 
and 1.80 ± 0.18 grams at 100 M CCh (n=54).  These force 
measurements are not normalized by mass and demonstrate the 
variability among strips used in the experiments.  However, all 
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strips serve as individual controls for the experimental 
treatments, and all statistical tests are suitably conducted on 
repeated measurements. 
Contraction at 1 and 2 min post exposure 
Measured tension at time points 1 minute and 2 minutes 
following the initial tension increase were compared to peak 
values and expressed as a percentage  At t=1 minute, the 
percentages of peak tension were 74.28% ± 4.32% for 10 nM CCh 
(n=16), 74.97% ± 3.09% for 1 M CCh (n=23), and 64.69% ± 4.23% 
for 100 M CCh (n=29).  At t=2 minutes, the percentage values 
respectively were 65.56% ± 6.67% (n=15), 62.85% ± 4.96% (n=26), 
and 47.87% ± 4.13% (n=29).  These data are summarized in Figure 
12. 
Area under the curve for control contractions 
Areas under the response curves were calculated for the first 
minute (AUC 0-1 min), second minute (AUC 1-2 min), and first two 
minutes (AUC 0-2 min).  For AUC 0-1 min, values were 16.79 ± 
2.83 gram-seconds at 10 nM CCh (n=35), 38.86 ± 5.09 gram-seconds 
at 1 μM CCh (n=42), and 77.25 ± 8.65 gram-seconds at 100 μM CCh 
(n=46).  For AUC 1-2 min, values were 22.85 ± 4.01 gram-seconds 
at 10 nM CCh (n=35), 46.89 ± 7.42 gram-seconds at 1 μM CCh 
(n=38), and 53.00 ± 7.09 gram-seconds at 100 μM CCh (n=44).  For 
AUC 0-2 min, values were 34.44 ± 5.84 gram-seconds at 10 nM CCh 
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(n=34), 83.62 ± 11.35 gram-seconds at 1 μM CCh (n=42), and 
133.25 ± 14.67 gram-seconds at 100 μM CCh (n=45).  A summary of 
this data is displayed in Figure 13. 
 72 
  
Figure 11. Control contractile response to carbachol. 
Grand mean of all responses.  (n=40 for 10 nM CCh, n=50 
for 1 μM CCh, and n=54 for 100 μM CCh).  
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Figure 12. Percentage of Peak Amplitude remaining at t = 1 min 
and t = 2 min for control responses. 
Sample sizes for t=1 minute: for 10 nM CCh (n=16), for 1 M 
CCh (n=23), and for 100 M CCh (n=29).  At t=2 minutes, 
respective sample sizes: n=15, n=26, and n=29. 
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Figure 13. AUC 0-1 min, AUC 1-2 min, and AUC 0-2 min data for 
control responses. 
Sample sizes range from 32 to 45 among the three metrics.   
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Repeated Measurements 
Repeated measurements of peak amplitude and area under the 
curve were conducted on strips in absence of kinase inhibition.  
This was to ensure that any change in contractile behavior is 
not an artifact of de-sensitization to agonist or strip fatigue.  
Strips were exposed to 1 μM CCh, contractions measured.  
Following a wash, strips were incubated for 15 min in Krebs 
solution, and dosed again with 1 μM CCh, to mimic the incubation 
period with kinase inhibitors.  Data are expressed as percentage 
of initial contraction/AUC.  Paired t-tests were conducted to 
assess significance between initial and repeated measurements. 
Peak Amplitude/Area under the curve repeated measurements 
Following a 15 min incubation after initial contraction, peak 
recorded tension in strips was 98.29% ± 3.99% of the initial 
recording (n=13, 5 animals).  Summary data displayed in Figure 
14.  Following a 15 min incubation period, strips exhibited 
contractions with AUC 0-1 min and AUC 0-2 min that were 99.00% ± 
2.148% (n=13, 5 animals) and 102.1% ± 1.881% (n=13, 5 animals) 
respectively.  No significant differences were seen with 
repeated measures (all P > 0.05).  These data are summarized in 
Figure 15. 
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Figure 14. Peak Contractions of Repeated Measurements. 
Repeated peak recorded tension in strips was 98.29% ± 3.99% of 
the initial recording (n=13, 5 animals).  No significance noted. 
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Figure 15. AUC 0-1 min and AUC 0-2 min values for repeated 
measurements. 
Repeated AUC 0-1 min and AUC 0-2 min values were 99.00% ± 
2.148% (n=13, 5 animals) and 102.1% ± 1.881% (n=13, 5 animals) 
of the original recordings.  No significance noted. 
 82 
  
 83 
Effects of Muscarinic Antagonism 
Contraction in longitudinal muscle is mediated primarily by m3 
receptors.  Smooth muscle cells expressed a greater number of m2 
receptors, but these receptors are not definitively involved in 
acute contractile behavior.  Strips were subjected to 1 μM CCh 
before and after incubation with methoctramine (m2 receptor 
antagonist) and 4-DAMP (m3 receptor antagonist).  Incubation 
with 1 μM methoctramine caused no significant changes to peak 
contraction, AUC 0-1 min, or AUC 0-2 min induced by 1 μM 
carbachol (all P > 0.05, n=7 from 4 animals).  Incubation with 1 
μM 4-DAMP prevented all responses to 1 μM carbachol (n=6).  
Results are summarized in Figure 16. 
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Figure 16. Effect of muscarinic antagonists on CCh-induced 
contraction. 
1 μM methoctramine showed no significant effect upon 1 μM CCh 
induced contraction.  1 μM 4-DAMP completed blocked all 
contraction induced by CCh. n=7 from 4 animals. 
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Effects of Neural Inhibition (TTX) 
Repeated measurements were conducted in the presence of 1 μM 
tetrodotoxin (TTX), a Na
+
 channel blocker, in order to 
investigate any neural influence on contractile behavior.  Peak 
contractions, contractions at 1 minute and 2 minutes, and area 
under the curve data were collected after 15 min incubation with 
TTX and compared to control contractions. 
Peak Contraction due to carbachol 
The peak contraction elicited by all concentrations of CCh was 
not significantly affected by TTX administration.  Viewed as 
percentage of control contraction, TTX exposure led to 
contractions 102.8% ± 5.98% of the control value at 1 μM CCh 
(n=7), 113.2% ± 8.6% at 10 μM CCh (n=7), and 110.5% ± 9.02% at 
100 μM CCh (n=7).  Again, although mean contractions were 
increased with TTX incubation, the values only approached 
significance (all P-Values > 0.05).  Summary data for Peak 
contraction in the presence of TTX is offered in Figure 17. 
Contraction at 1 min and 2 min minutes post exposure 
Contraction at 1 min and 2 minute was recorded under control 
conditions and after incubation with TTX.  Raw values and 
percent of peak contraction are offered.  As with the peak 
contraction, 1 μM TTX cause no significant change in the 
amplitude of contraction at t = 1 minute and t = 2 minutes.  A t 
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= 1 minute, control versus TTX had amplitudes (in grams) of 1.85 
± 0.13 versus 1.78 ± 0.12 for 1 μM CCh (n=5), 2.14 ± 0.20 versus 
2.04 ± 0.16 grams for 10 μM CCh (n=5), and 2.39 ± 0.19 versus 
2.10 ± 0.14 grams for 100 μM CCh (n=5).  At t = 2 minutes, 
control versus TTX had amplitudes (in grams) of 1.67 ± 0.05 
versus 1.49 ± 0.07 for 1 μM CCh (n=5), 1.79 ± 0.21 versus 1.62 ± 
0.07 grams for 10 μM CCh (n=5), and 1.76 ± 0.08 versus 1.80 ± 
0.11 grams for 100 μM CCh (n=5).  These data and percent 
summaries are included in Figure 18.  
Area under curve for first two minutes 
Similarly, 1 μM TTX has no significant effect upon the area 
under the curve for the first minute and first two minutes of 
contractions elicited by CCh at all tested concentrations. For 
AUC 0-1 min, control versus TTX had values (in gram-seconds) of 
63.25 ± 10.64 for versus 60.42 ± 9.23 for 1 μM CCh (n=5), 104.3 
± 13.28 versus 121.2 ± 18.82 grams for 10 μM CCh (n=5), and 
112.9 ± 13.27 versus 128.5 ± 27.21 grams for 100 μM CCh (n=5).  
 For AUC 0-2 min, control versus TTX had values (in gram-
seconds) of 106.5 ± 18.73 for versus 98.44 ± 12.09 for 1 μM CCh 
(n=5), 149.3 ± 23.02 versus 183.2 ± 31.53 grams for 10 μM CCh 
(n=5), and 192.5 ± 32.68 versus 220.0 ± 38.89 grams for 100 μM 
CCh (n=5).   These data and percent summaries are included in 
Figure 19. 
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Figure 17. Peak Contraction Data in the presence of TTX versus 
control. 
102.8% ± 5.98% of control at 1 μM CCh (n=7), 113.2% ± 8.6% at 10 μM 
CCh (n=7), and 110.5% ± 9.02% at 100 μM CCh (n=7).  No significance 
determined. 
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Figure 18. Contractions at 1 min and 2 min in the presence of TTX 
versus control. 
No significant difference in contractions at 1 min and 2 min post 
carbachol in TTX-incubated group versus control group.  n = 5 from 
at least three animals. 
 91 
  
 92 
  
Figure 19. AUC 0-1 min and AUC 0-2 min values in the presence 
of TTX versus control. 
No significant differences noted in AUC values between TTX 
group and carbachol group.  n = 5 minimum from at least 3 
animals. 
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Effects of Rho Kinase Inhibition (Y27632) 
Rho kinase is known to affect the phosphatase leg of 
contractile regulation through its direct phosphorylation of 
MYPT1 and its indirect phosphorylation of CPI-17 via PLD-DAG-
PKC.  Incubation of strips for 15 minutes in 10 μM Y27632 (a 
powerful Rho Kinase inhibitor) allows for comparison of Rho-
kinase inhibited contraction to control conditions.  Rho kinase 
inhibition was viewed from the contractile perspectives of basal 
tone regulation, peak contraction, contraction at one and two 
minutes post CCh exposure, and area under the curve values.  The 
possible effect of Rho kinase inhibition on MLCK activity was 
studied via molecular methods.  
Basal Activity 
Rho kinase inhibition led to a significant decrease in basal 
tone after 10 minutes of incubation.  In studied strips (n=15), 
administration of Y27632 (Rho kinase inhibition) resulted in a 
change of basal tone from 0.82 ± 0.07 grams to 0.73 ± 0.06 
grams.  A conducted paired t-test returned P < 0.01; the 
inhibition of Rho kinase reduces basal tone.  Data summarized 
and displayed in Figure 20.   
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Figure 20. Effect of Rho Kinase inhibition on basal tone. 
Administration of 10 μM Y27632 for 10 min resulted in a 
reduction of basal tone from 0.82 ± 0.07 grams to 0.73 ± 0.06 
grams (* indicates P < 0.05, n=12).   
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Peak Contraction due to carbachol 
Rho kinase inhibition (via Y27632 incubation) significantly 
reduced contraction for carbachol concentrations of 1 μM and 100 
μM.  Control peak contraction values (in grams) versus 
contractions following Y27632 incubation are 0.80 ± 0.30 versus 
0.30 ± 0.08 (P > 0.05, n=4) at 10 nM CCh; 1.13 ± 0.28 versus 
0.71 ± 0.19 (P < 0.01, n=15) for 1 μM CCh; and 2.17 ± 0.38 
versus 1.21 ± 0.23 (P < 0.05, n=16) at 100 μM CCh.  Summary data 
are displayed in Figure 21. 
Contraction at 1 min and 2 min minutes post exposure 
Rho kinase inhibition reduced the contraction at both 1 min 
and 2 min post CCh exposure for all concentrations of CCh.  With 
10 nM CCh, 1 minute control values (in grams) versus Y27632 
incubation were 1.34 ± 0.17 versus 0.72 ± 0.15 (P < 0.05), 2 
minute values were 1.11 ± 0.06 for control versus 0.64 ± 0.08 
for Y27632 incubation (P < 0.01, both n=3); for 1 μM CCh, 1 
minute control values (in grams) were 1.76 ± 0.31 versus 0.83 ± 
0.11 (P < 0.05), 2 minute values were 1.45 ± 0.22 for control 
versus 0.77 ± 0.10 grams for Y27632 incubation (P < 0.05, both 
n=6); for 100 μM CCh, 1 minute control values (in grams) versus 
Y27632 incubation were 1.70 ± 0.21 versus 1.14 ± 0.18 (P < 
0.01), 2 minute control values were 1.48 ± 0.16 versus 1.08 ± 
0.15 for Y27632 incubation (P < 0.01, both n=9).  Data 
summarized in Figure 22. 
 98 
 
  
Figure 21. Effect of Rho Kinase Inhibition on Peak Contraction. 
Top Panel: Rho Kinase inhibition significantly reduced peak 
contraction elicited by 1 μM CCh (1.13 ± 0.28 versus 0.71 ± 0.19 
grams, n=15) and by 100 μM CCh (2.17 ± 0.38 versus 1.21 ± 0.23 
grams, n=16). (* = P < 0.05) 
Bottom Panel: Summary data expressed as percentage of control.    
(* = P < 0.05) 
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Figure 22. Effect of Rho Kinase Inhibition at 1 min and 2 min 
post CCh exposure. 
Top Panel: Tone was reduced at t = 1 min and t = 2 min with 
Rho kinase inhibition. Sample Sizes range from 3 to 9. (* = P < 
0.05) 
Bottom Panel: t = 1 min and t = 2 min data expressed by 
percentage of control. 
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Area under curve for first two minutes 
Rho Kinase inhibition caused a significant decrease in the 
area under the curve metric in the first (AUC 0-1), second (AUC 
1-2), and first two minutes (AUC 0-2) for contractions elicited 
by 1 μM and 100 μM CCh.  AUC data for 10 nM CCh contractions 
were not significantly reduced.  For AUC 0-1 min, control versus 
Y27632 incubation values (in gram-seconds): for 100 nM CCh, 
13.08 ± 8.85 versus 3.608 ± 2.00 (P > 0.05, n=5); for 1 μM CCh, 
46.05 ± 9.86 versus 15.02 ± 3.56 (P < 0.01, n=13); for 100 μM 
CCh, 85.81 ± 15.41 versus 42.86 ± 7.68 (P < 0.01, n=16).  For 
AUC 1-2 min, control versus Y27632 incubation values (in gram-
seconds): for 100 nM CCh, 14.93 ± 9.17 versus 3.917 ± 1.87 (P > 
0.05, n=3); for 1 μM CCh, 64.13 ± 15.90 versus 21.83 ± 5.48 (P < 
0.01, n=13); for 100 μM CCh, 56.82 ± 12.61 versus 31.06 ± 6.07 
(P < 0.05, n=15).  For AUC 0-2 min, control versus Y27632 
incubation values (in gram-seconds): for 100 nM CCh, 35.54 ± 
24.26 versus 9.503 ± 5.223 (P > 0.05, n=3); for 1 μM CCh, 120.8 
± 25.15 versus 39.90 ± 9.417 (P < 0.01, n=10); for 100 μM CCh, 
142.7 ± 26.03 versus 74.87 ± 13.31 (P < 0.01, n=15).  Summary 
data for AUC values is presented in Figure 23. 
  
 103 
 
  
Figure 23. Effect of Rho kinase inhibition on AUC values. 
 Top Panel: Raw data values of AUC 0-1 min, AUC 1-2 min,    
and AUC 0-2 min for CCh concentrations of 10 nM, 1 μM, and 100 
μM. Sample sizes range from 5 to 16. (* indicates P < 0.05) 
 Bottom Panel: Data expressed as percentage of control. 
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MLCK activity 
The effect of Rho kinase inhibition on MLCK activity was 
measured using immunokinase assay.  MLCK activity was measured 
in longitudinal muscle-myenteric plexus (LM-MP) strip 
homogenates of four groups: control, following 10 min incubation 
of 10 μM Y27632, 1 min post 1 μM CCh exposure, and 1 min post 1 
μM CCh exposure following 10 min incubation with 10 μM Y27632.  
1 μM CCh increased MLCK activity to 167% ± 21% of control 
activity (P < 0.05 versus control, n = 12).  Incubation for 10 
min with Y27632 reduced CCh-induced activity to 122% ± 11% of 
control activity (P < 0.05 versus control, n = 8).  Incubation 
of Y27632 alone did not differ MLCK from control (n = 12 for 
control, n = 4 for Y27632 alone).  CCh-induced activity was not 
significantly varied between strips with and without Rho Kinase 
inhibition (n = 12 for CCh, n = 8 for CCh with Y27632 
incubation).  Results are shown in Figure 24. 
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Figure 24.  Effect of Rho Kinase Inhibition on CCh-evoked MLCK 
activity. 
1 μM CCh-induced MLCK activities with and without Rho Kinase 
inhibition are presented.  Values expressed as percentage ± SEM 
of control MLCK activity.  Control, n = 12.  CCh-induced 
activity is 167% ± 21% of control (P < 0.05, n = 12).  CCh 
activity in the presence of 10 μM Y27632 reduces CCh-induced 
activity to 122% ± 11% of control (P < 0.05, n = 8).   
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Effects of ERK1/2 Inhibition (PD98059) 
Incubation of strips for 15 minutes in 10 μM PD98059 (an 
ERK1/2 inhibitor) allows for comparison of ERK1/2 inhibited 
contraction to control conditions.  ERK1/2 inhibition was viewed 
from the contractile perspectives of basal tone regulation, peak 
contraction, contraction at one and two minutes post CCh 
exposure, and area under the curve values.  Possible additive 
effects of ERK1/2 inhibition (postulated to work as kinase 
regulator) and Rho Kinase inhibition (known phosphatase 
regulator) are studied.  The effect of ERK1/2 inhibition on MLCK 
activity was studied via molecular methods.  
Basal Activity 
ERK1/2 inhibition led to no significant change in basal tone 
after 10 minutes of incubation.  In studied strips (n=12), 
administration of PD98059 (ERK1/2 inhibition) resulted in a 
change of basal tone from 0.79 ± 0.06 grams to 0.81 ± 0.05 
grams.  A conducted paired t-test returned P > 0.05; the 
inhibition of ERK1/2 does not affect basal tone.  Data 
summarized and displayed in Figure 25. 
Peak Contraction due to carbachol 
ERK1/2 inhibition (via PD98059 incubation) significantly 
reduced contraction for all carbachol concentrations.  Control 
peak contraction values (in grams) versus contractions following 
 109 
PD98059 incubation are 0.47 ± 0.13 versus 0.28 ± 0.08 (P < 0.05, 
n=6) at 10 nM CCh; 0.86 ± 0.13 versus 0.49 ± 0.09 (P < 0.01, 
n=9) for 1 μM CCh; and 2.06 ± 0.38 versus 1.40 ± 0.32 (P < 
0.001, n=9) for 100 μM CCh.  Summary data are displayed in 
Figure 26. 
Contraction at 1 min and 2 min minutes post exposure 
ERK1/2 inhibition reduced the contraction at both 1 min and 2 
min post CCh exposure for all concentrations of CCh.  With 10 nM 
CCh, 1 minute control values (in grams) versus PD98059 
incubation were 1.07 ± 0.15 versus 0.90 ± 0.14 (P < 0.01), 2 
minute values were 0.88 ± 0.09 for control versus 0.77 ± 0.09 
for PD98059 incubation (P < 0.01, both n=4); for 1 μM CCh, 1 
minute control values (in grams) were 1.56 ± 0.12 versus 1.13 ± 
0.08 (P < 0.01), 2 minute values were 1.36 ± 0.14 for control 
versus 1.01 ± 0.05 grams for PD98059 incubation (P < 0.01, both 
n=4); for 100 μM CCh, 1 minute control values (in grams) versus 
PD98059 incubation were 1.86 ± 0.13 versus 1.45 ± 0.11 (P < 
0.01), 2 minute control values were 1.54 ± 0.12 versus 1.15 ± 
0.09 for PD98059 incubation (P < 0.01, both n=4).  Data 
summarized in Figure 27. 
Area under curve for first two minutes 
ERK1/2 inhibition caused a significant decrease in the area 
under the curve metric in the first (AUC 0-1), second (AUC 1-2), 
 110 
and first two minutes (AUC 0-2) for contractions elicited by 1 
μM and 100 μM CCh.  AUC values for 10 nM CCh contractions were 
significantly reduced only for the AUC 0-1 min segment.  For AUC 
0-1 min, control versus PD98059 incubation values (in gram-
seconds): for 10 nM CCh, 18.92 ± 4.19 versus 11.07 ± 2.25 (P > 
0.05, n=4); for 1 μM CCh, 42.06 ± 8.11 versus 22.18 ± 4.70 (P < 
0.05, n=6); for 100 μM CCh, 83.18 ± 14.69 versus 54.59 ± 10.46 
(P < 0.01, n=9).  For AUC 1-2 min, control versus PD98059 
incubation values (in gram-seconds): for 10 nM CCh, 19.27 ± 4.56 
versus 11.73 ± 2.78 (P < 0.05, n=4); for 1 μM CCh, 48.45 ± 10.45 
versus 24.58 ± 3.25 (P < 0.05, n=7); for 100 μM CCh, 58.07 ± 
10.41 versus 33.06 ± 7.19 (P < 0.01, n=9).  For AUC 0-2 min, 
control versus PD98059 incubation values (in gram-seconds): for 
10 nM CCh, 31.22 ± 9.69 versus 18.78 ± 5.57 (P > 0.05, n=7); for 
1 μM CCh, 87.82 ± 17.61 versus 47.16 ± 6.56 (P < 0.01, n=7); for 
100 μM CCh, 141.3 ± 23.86 versus 87.66 ± 16.69 (P < 0.01, n=9).  
Summary data for AUC values is presented in Figure 28. 
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Figure 25. Effect of ERK1/2 Inhibition on Basal Tone. 
Administration of 10 μM PD98059 for 10 min resulted in no 
significant reduction of basal tone (0.79 ± 0.06 grams versus 
0.81 ± 0.05 grams, n=12).   
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Figure 26. Effect of ERK 1/2 Inhibition on Peak Contraction. 
Top Panel: Summary data expressed as percentage of control.    
(* = P < 0.05) 
Bottom Panel: ERK1/2 inhibition significantly reduced peak 
contraction elicited by 10 nM CCh (0.47 ± 0.13 versus 0.28 ± 
0.08, n=6), 1 μM CCh (0.86 ± 0.13 versus 0.49 ± 0.09 grams, n=9) 
and by 100 μM CCh (2.06 ± 0.38 versus 1.40 ± 0.32 grams, n=9. (* 
= P < 0.05) 
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Figure 27. Effect of ERK 1/2 Inhibition on contraction at 1 
min and 2 min post CCh exposure. 
Top Panel: Tone was reduced at t = 1 min and t = 2 min with 
ERK1/2 inhibition. n=4 for all sets. (* = P < 0.05) 
Bottom Panel: t = 1 min and t = 2 min data expressed by 
percentage of control. 
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Figure 28. Effects of ERK1/2 Inhibition on AUC Values. 
 Top Panel: Raw data values of AUC 0-1 min, AUC 1-2 min,    
and AUC 0-2 min for CCh concentrations of 10 nM, 1 μM, and 100 
μM. Sample sizes range from 4 to 9. (* indicates P < 0.05) 
 Bottom Panel: Data expressed as percentage of control. 
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Combination Effects with Rho Kinase inhibition 
ERK1/2 inhibitor PD98059 was used in concert with Rho Kinase 
inhibitor Y27632 to observe any additive effect.  In 6 strips so 
tested, both 10 μM PD98059 alone and 10 μM PD98059 with 10 μM 
Y27632 significantly inhibited contraction elicited by 1 μM CCh: 
1.17 ± 0.19 grams for Control, 0.96 ± 0.14 grams for PD98059 
alone (P < 0.05), 0.85 ± 0.13 grams for both inhibitors (P < 
0.05).  However, there was no significant difference between the 
single inhibitor PD98059 and the use of both inhibitors 
simultaneously.  These results are displayed in Figure 29. 
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Figure 29. Combination effects of ERK1/2 and Rho Kinase 
Inhibition on Amplitude. 
10 μM PD98059 alone and with 10 μM Y27632 (Rho kinase 
inhibition) significantly reduced peak contraction as compared 
to control.  Additive effects were not observed.  (n=6, * 
indicates P < 0.05) 
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MLCK activity  
The effect of ERK1/2 inhibition on MLCK activity was measured 
using immunokinase assay.  MLCK activity was measured in 
longitudinal muscle-myenteric plexus (LM-MP) strip homogenates 
of four groups: control, following 10 min incubation of 10 μM 
PD98059, 1 min post 1 μM CCh exposure, and 1 min post 1 μM CCh 
exposure following 10 min incubation with 10 μM PD98059.  1 μM 
CCh increased MLCK activity to 167% ± 21% of control activity (P 
< 0.05 versus control, n = 12).  Incubation for 10 min with 
PD98059 lead to CCh-induced activity that was 119% ± 21% of 
control activity (P > 0.05, n = 8).  Incubation of PD98059 alone 
did not differ MLCK from control (n = 12 for control, n = 4 for 
PD98059 alone).  CCh-induced activity was not significantly 
varied between strips with and without ERK1/2 inhibition (n = 12 
for CCh, n = 8 for CCh with ERK1/2 incubation).  Results are 
shown in Figure 30. 
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Figure 30. Effect of ERK1/2 Inhibition on CCh-evoked MLCK 
activity. 
1 μM CCh-induced MLCK activities with and without ERK1/2 
inhibition are presented.  Values expressed as percentage ± SEM 
of control MLCK activity.  Control, n = 12.  CCh-induced 
activity is 167% ± 21% of control (P < 0.05, n = 12).  CCh-
induced activity in the presence of 10 μM PD98059 was 122% ± 11% 
of control (P > 0.05, n = 8).   
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Effects of CaMKK/AMPK Inhibition (STO-609) 
Incubation of strips for 15 minutes in 10 μM STO-609 (a 
CaMKK/AMPK inhibitor) allows for comparison of CaMKK/AMPK 
inhibited contractions to control conditions.  CaMKK/AMPK 
inhibition was viewed from the contractile perspective in basal 
tone regulation, peak contraction, contraction at one and two 
minutes post CCh exposure, and area under the curve values.  The 
effect of CaMKK/AMPK inhibition on MLCK activity was studied via 
molecular methods.  
 
Basal Activity 
CaMKK/AMPK inhibition led to no significant change in basal 
tone after 10 minutes of incubation.  In strips so studied 
(n=7), administration of STO-609 (CaMKK/AMPK inhibition) 
resulted in a change of basal tone from 0.76 ± 0.10 grams to 
0.74 ± 0.10 grams.  A conducted paired t-test returned P > 0.05; 
the inhibition of CaMKK/AMPK has no effect upon basal tone.  
Data summarized and displayed in Figure 31.   
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Peak Contraction due to carbachol 
CaMKK/AMPK inhibition (via STO-609 incubation) significantly 
reduced contraction for carbachol concentrations of 1 μM and 100 
μM.  Control peak contraction values (in grams) versus 
contractions following STO-609 incubation are 0.51 ± 0.16 versus 
0.32 ± 0.14 (P > 0.05, n=6) at 10 nM CCh; 1.31 ± 0.20 versus 
0.81 ± 0.15 (P < 0.01, n=23) for 1 μM CCh; and 1.96 ± 0.37 
versus 1.22 ± 0.20 (P < 0.05, n=16) for 100 μM CCh.  Summary 
data are displayed in Figure 32. 
 
Contraction at 1 min and 2 min minutes post exposure 
CaMKK/AMPK inhibition significant reduced the contraction at 
both 1 min and 2 min post CCh exposure for CCh concentrations of 
10 nM and 1 μM.  With 10 nM CCh, 1 minute control values (in 
grams) versus STO-609 incubation were 1.18 ± 0.16 versus 0.86 ± 
0.09 (P < 0.05), 2 minute values were 1.15 ± 0.17 for control 
versus 0.86 ± 0.10 for STO-609 incubation (P < 0.05, both n=4); 
for 1 μM CCh, 1 minute control values (in grams) were 1.54 ± 
0.19 versus 1.29 ± 0.18 (P < 0.01), 2 minute values were 1.37 ± 
0.18 for control versus 1.17 ± 0.16 grams for STO-609 incubation 
(P < 0.05, both n=16); for 100 μM CCh, 1 minute control values 
(in grams) versus STO-609 incubation were 1.63 ± 0.23 versus 
1.33 ± 0.29 (P > 0.05), 2 minute control values were 1.31 ± 0.25 
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versus 0.98 ± 0.19 for STO-609 incubation (P > 0.06, both n=6).  
Data summarized in Figure 33. 
 
Area under curve for first two minutes 
CaMKK/AMPK inhibition caused a significant decrease in the 
area under the curve metric in the first (AUC 0-1), second (AUC 
1-2), and first two minutes (AUC 0-2) for all CCh contractions.  
AUC values for 10 nM CCh contractions were not significantly 
reduced.  For AUC 0-1 min, control versus STO-609 incubation 
values (in gram-seconds): for 10 nM CCh, 28.99 ± 3.03 versus 
15.23 ± 1.59 (P < 0.01, n=5); for 1 μM CCh, 52.88 ± 10.26 versus 
38.36 ± 7.19 (P < 0.01, n=13); for 100 μM CCh, 91.68 ± 20.41 
versus 48.86 ± 8.78 (P < 0.05, n=9).  For AUC 1-2 min, control 
versus STO-609 incubation values (in gram-seconds): for 10 nM 
CCh, 33.5 ± 5.57 versus 22.39 ± 3.58 (P < 0.05, n=4); for 1 μM 
CCh, 52.06 ± 10.40 versus 35.00 ± 5.54 (P < 0.05, n=17); for 100 
μM CCh, 56.69 ± 13.85 versus 36.90 ± 6.71 (P < 0.05, n=9).  For 
AUC 0-2 min, control versus STO-609 incubation values (in gram-
seconds): for 10 nM CCh, 62.64 ± 5.40 versus 40.46 ± 4.61 (P < 
0.01, n=7); for 1 μM CCh, 85.42 ± 13.77 versus 54.67 ± 7.92 (P < 
0.01, n=15); for 100 μM CCh, 114.6 ± 16.23 versus 81.29 ± 13.01 
(P < 0.01, n=9).  Summary data for AUC values is presented in 
Figure 34. 
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Figure 31. Effect of CaMKK/AMPK inhibition on basal tone. 
Administration of 10 μM STO-609 for 10 min resulted in no 
significant reduction of basal tone (0.76 ± 0.10 grams versus 
0.71 ± 0.10 grams, n=7).   
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Figure 32. Effect of CaMKK/AMPK inhibtion on peak contraction. 
Top Panel: CaMKK/AMPK inhibition significantly reduced peak 
contraction elicited by 1 μM CCh (1.31 ± 0.20 versus 0.81 ± 0.15 
grams, n=9) and by 100 μM CCh (1.96 ± 0.37 versus 1.22 ± 0.20 
grams, n=9. (* = P < 0.05)  
Bottom Panel: Summary data expressed as percentage of control.    
(* = P < 0.05) 
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Figure 33. Effect of CaMKK/AMPK inhibition on contractions at 
1 min and 2 min post CCh exposure. 
Top Panel: Tone was reduced at t = 1 min and t = 2 min with 
Rho kinase inhibition. Sample Sizes range from 4 to 16. (* = P < 
0.05) 
Bottom Panel: t = 1 min and t = 2 min data expressed by 
percentage of control. 
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Figure 34. Effects of CaMKK/AMPK Inhibition on AUC values. 
 Top Panel: Raw data values of AUC 0-1 min, AUC 1-2 min,    
and AUC 0-2 min for CCh concentrations of 10 nM, 1 μM, and 100 
μM. Sample sizes range from 5 to 16. (* indicates P < 0.05) 
 Bottom Panel: Data expressed as percentage of control. 
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Combination Effects with Rho Kinase inhibition 
CaMKK/AMPK inhibitor STO-609 was used in concert with Rho 
Kinase inhibitor Y27632 to observe any additive effect.  In 7 
strips so tested, both 10 μM STO-609 alone and 10 μM STO-609 
with 10 μM Y27632 significantly inhibited peak contraction 
elicited by 1 μM CCh: 1.57 ± 0.32 grams for Control, 1.31 ± 0.24 
grams for STO-609 alone (P < 0.05), 0.89 ± 0.18 grams for both 
inhibitors (P < 0.01).  In addition, the contraction elicited by 
1 μM CCh in the presence of both inhibitors was significantly 
lower than with STO-609 alone (P < 0.05).  There is a 
significant additive effect of CaMKK/AMPK inhibition and Rho 
Kinase inhibition on peak contraction. 
A similar additive effect was seen on AUC values 0-1 min and 
0-2 min.  For the 0-1 min AUC metric, control values (in gram-
seconds) were 66.84 ± 14.99 versus 52.24 ± 10.47 for STO-609 
alone (P < 0.05, n=7) and 28.17 ± 4.31 for both inhibitors.  The 
value in the presence of both inhibitors was significantly less 
than with STO-609 alone (P < 0.05, n=7).  For the 0-2 min AUC 
metric, control values (in gram-seconds) were 142.6 ± 131.86 
versus 122.4 ± 26.22 for STO-609 alone (P < 0.05, n=7) and 68.36 
± 9.72 for both inhibitors (P < 0.05, n=7).  The value in the 
presence of both inhibitors was significantly less than with 
STO-609 alone (P < 0.05, n=7).  These results are visualized in 
Figure 35. 
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Figure 35. Combined Effects of CaMKK/AMPK and Rho Kinase 
Inhibition. 
Top Panel: Effects of CaMKK/AMPK inhibition with Rho kinase 
inhibition on peak contraction are additive. (n=7, * indicates P 
< 0.05). 
Middle Panel: Effects of CaMKK/AMPK inhibition with Rho kinase 
inhibition on AUC 0-1 min are additive. (n=7, * indicates P < 
0.05). 
Bottom Panel: Effects of CaMKK/AMPK inhibition with Rho kinase 
inhibition on AUC 0-2 min are additive. (n=7, * indicates P < 
0.05). 
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MLCK activity  
The effect of CaMKK/AMPK inhibition on MLCK activity was 
measured using immunokinase assay.  MLCK activity was measured 
in longitudinal muscle-myenteric plexus (LM-MP) strip 
homogenates of four groups: control, following 10 min incubation 
of 10 μM STO-609, 1 min post 1 μM CCh exposure, and 1 min post 1 
μM CCh exposure following 10 min incubation with 10 μM STO-609.  
1 μM CCh increased MLCK activity to 167% ± 21% of control 
activity (P < 0.05 versus control, n = 12).  Incubation for 10 
min with STO-609 reduced CCh-induced activity to 146% ± 19% of 
control activity (P < 0.05 versus control, n = 8).  Incubation 
of STO-609 alone did not differ MLCK from control (n = 12 for 
control, n = 4 for STO-609 alone).  CCh-induced activity was not 
significantly varied between strips with and without CaMKK/AMPK 
inhibition (n = 12 for CCh, n = 8 for CCh with STO-609 
incubation).  Results are shown in Figure 36. 
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Figure 36. Effect of CaMKK/AMPK inhibition on CCh-evoked MLCK 
activity. 
1 μM CCh-induced MLCK activities with and without CaMKK/AMPK 
inhibition are presented.  Values expressed as percentage ± SEM 
of control MLCK activity.  Control, n = 12.  CCh-induced 
activity is 167% ± 21% of control (P < 0.05, n = 12).  CCh 
activity in the presence of 10 μM STO-609 reduces CCh-induced 
activity to 146% ± 19% of control (P < 0.05, n = 8).   
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Effects of CaMKII Inhibition (KN62) 
Incubation of strips for 15 minutes in 10 μM KN62 (a CaMKII 
inhibitor) allows for comparison of CaMKII inhibited 
contractions to control conditions.  CaMKII inhibition was 
viewed from the contractile perspective of basal tone 
regulation, peak contraction, contraction at one and two minutes 
post CCh exposure, and area under the curve values.  Additive 
effects of CaMKII inhibition with Rho Kinase inhibition were 
tested.  The effect of CaMKII inhibition on MLCK activity was 
studied via molecular methods.  
Basal Activity 
CaMKII inhibition led to a significant decrease in basal tone 
after 10 minutes of incubation.  In studied strips (n=8), 
administration of KN62 (CaMKII inhibition) resulted in a change 
of basal tone from 0.61 ± 0.07 grams to 0.53 ± 0.07 grams.  A 
conducted paired t-test returned P < 0.05; the inhibition of 
CaMKII reduces basal tone.  Data summarized and displayed in 
Figure 37.   
 
Peak Contraction due to carbachol 
CaMKII inhibition (via KN62 incubation) significantly reduced 
contraction for all concentrations of carbachol.  Control peak 
contraction values (in grams) versus contractions following KN62 
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incubation are 0.52 ± 0.14 versus 0.34 ± 0.12 (P < 0.05, n=7) at 
10 nM CCh; 0.74 ± 0.10 versus 0.46 ± 0.05 (P < 0.01, n=13) for 1 
μM CCh; and 1.35 ± 0.32 versus 0.64 ± 0.15 (P < 0.05, n=7) at 
100 μM CCh.  Summary data are displayed in Figure 38. 
 
Contraction at 1 min and 2 min minutes post exposure 
CaMKII inhibition reduced the contraction at both 1 min and 2 
min post CCh exposure for all concentrations of CCh.  With 10 nM 
CCh, 1 minute control values (in grams) versus KN62 incubation 
were 0.71 ± 0.07 versus 0.52 ± 0.06 (P < 0.05), 2 minute values 
were 0.67 ± 0.07 for control versus 0.51 ± 0.07 for KN62 
incubation (P < 0.05, both n=4); for 1 μM CCh, 1 minute control 
values (in grams) were 1.28 ± 0.10 versus 0.99 ± 0.11 (P < 
0.01), 2 minute values were 1.15 ± 0.1 for control versus 0.94 ± 
0.10 grams for KN62 incubation (P < 0.05, both n=11); for 100 μM 
CCh, 1 minute control values (in grams) versus KN62 incubation 
were 1.33 ± 0.18 versus 0.81 ± 0.08 (P < 0.05, n=5), 2 minute 
control values were 1.11 ± 0.16 versus 0.74 ± 0.08 for KN62 
incubation (P < 0.05, n=4).  Data summarized in Figure 39. 
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Area under curve for first two minutes 
CaMKII inhibition caused a significant decrease in the area 
under the curve metric in the first (AUC 0-1), second (AUC 1-2), 
and first two minutes (AUC 0-2) for contractions elicited by 1 
μM and 100 μM CCh.  AUC data for 10 nM CCh contractions were 
significantly reduced only for the AUC 0-1 min measurement.  For 
AUC 0-1 min, control versus KN62 incubation values (in gram-
seconds): for 10 nM CCh, 8.59 ± 2.46 versus 5.48 ± 1.44 (P < 
0.05, n=5); for 1 μM CCh, 36.98 ± 6.03 versus 20.89 ± 2.89 (P < 
0.05, n=11); for 100 μM CCh, 58.47 ± 14.21 versus 33.00 ± 7.09 
(P < 0.05, n=7).  For AUC 1-2 min, control versus KN62 
incubation values (in gram-seconds): for 10 nM CCh, 11.20 ± 4.73 
versus 7.68 ± 3.45 (P > 0.05, n=5); for 1 μM CCh, 36.24 ± 5.62 
versus 23.69 ± 3.6 (P < 0.01, n=11); for 100 μM CCh, 46.24 ± 
4.25 versus 34.84 ± 3.33 (P < 0.05, n=7).  For AUC 0-2 min, 
control versus KN62 incubation values (in gram-seconds): for 10 
nM CCh, 22.13 ± 10.10 versus 16.14 ± 7.43 (P > 0.05, n=4); for 1 
μM CCh, 69.38 ± 11.85 versus 42.11 ± 5.99 (P < 0.05, n=12); for 
100 μM CCh, 100.7 ± 18.58 versus 63.46 ± 10.27 (P < 0.05, n=5).  
Summary data for AUC values is presented in Figure 40. 
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Figure 37. Effect of CaMKII inhibition on basal tone. 
Administration of 10 μM KN62 for 10 min resulted in 
significant reduction of basal tone from 0.61 ± 0.07 grams to 
0.53 ± 0.07 grams (P < 0.05, n=6).  * = P < 0.05 
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Figure 38. Effect of CaMKII inhibition on peak contraction. 
Top Panel: CaMKII inhibition significantly reduced peak 
contraction elicited by 10 nM CCh (0.52 ± 0.14 versus 0.34 ± 
0.12, n=7), 1 μM CCh (0.74 ± 0.10 versus 0.46 ± 0.05 grams, 
n=13) and by 100 μM CCh (1.35 ± 0.32 versus 0.64 ± 0.15 grams, 
n=7. (* = P < 0.05) 
Bottom Panel: Summary data expressed as percentage of control.    
(* = P < 0.05) 
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Figure 39. Effect of CaMKII inhibition on contractions at 1 
min and 2 min post CCh exposure. 
Top Panel: Tone was reduced at t = 1 min and t = 2 min with 
Rho kinase inhibition. Sample Sizes range from 4 to 11. (* = P < 
0.05) 
Bottom Panel: t = 1 min and t = 2 min data expressed by 
percentage of control. 
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Figure 40. Effect of CaMKII inhibition on AUC values. 
 Top Panel: Raw data values of AUC 0-1 min, AUC 1-2 min,    
and AUC 0-2 min for CCh concentrations of 10 nM, 1 μM, and 100 
μM. Sample sizes range from 5 to 16. (* indicates P < 0.05) 
 Bottom Panel: Data expressed as percentage of control. 
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Combination Effects with Rho Kinase inhibition 
CaMKII inhibitor KN62 was used in concert with Rho Kinase 
inhibitor Y27632 to observe any additive effect.  In 8 strips so 
tested, both 10 μM KN62 alone and 10 μM KN62 with 10 μM Y27632 
significantly inhibited peak contraction elicited by 1 μM CCh: 
0.92 ± 0.09 grams for Control, 0.60 ± 0.05 grams for KN62 alone 
(P < 0.05), 0.36 ± 0.06 grams for both inhibitors (P < 0.05).  
In addition, the contraction elicited by 1 μM CCh in the 
presence of both inhibitors was significantly lower than with 
KN62 alone (P < 0.05).  There is a significant additive effect 
of CaMKII inhibition and Rho Kinase inhibition on peak 
contraction. 
A similar additive effect was seen on AUC values 0-1 min and 
0-2 min.  For the 0-1 min AUC metric, control values (in gram-
seconds) were 39.64 ± 5.21 versus 24.52 ± 2.67 for KN62 alone (P 
< 0.05, n=8) and 11.47 ± 2.89 for both inhibitors.  The value in 
the presence of both inhibitors was significantly less than with 
KN62 alone (P < 0.05, n=8).  For the 0-2 min AUC metric, control 
values (in gram-seconds) were 80.97 ± 11.84 versus 51.43 ± 4.00 
for KN62 alone (P < 0.05, n=8) and 34.70 ± 3.18 for both 
inhibitors (P < 0.05, n=8).  The value in the presence of both 
inhibitors was significantly less than with KN62 alone (P < 
0.05, n=7).  These results are summarized in Figure 41.  
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Figure 41.  Combined Effects of CaMKII and Rho Kinase 
inhibition. 
Top Panel: Effects of CaMKII inhibition with Rho kinase 
inhibition on peak contraction are additive. (n=8, * indicates P 
< 0.05). 
Middle Panel: Effects of CaMKII inhibition with Rho kinase 
inhibition on AUC 0-1 min are additive. (n=8, * indicates P < 
0.05). 
Bottom Panel: Effects of CaMKII inhibition with Rho kinase 
inhibition on AUC 0-2 min are additive. (n=8, * indicates P < 
0.05). 
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MLCK activity  
The effect of CaMKII inhibition on MLCK activity was measured 
using immunokinase assay.  MLCK activity was measured in 
longitudinal muscle-myenteric plexus (LM-MP) strip homogenates 
of four groups: control, following 10 min incubation of 10 μM 
KN62, 1 min post 1 μM CCh exposure, and 1 min post 1 μM CCh 
exposure following 10 min incubation with 10 μM KN62.  1 μM CCh 
increased MLCK activity to 167% ± 21% of control activity (P < 
0.05 versus control, n = 12).  Incubation for 10 min with Y27632 
reduced CCh-induced activity to 140% ± 14% of control activity 
(P < 0.05 versus control, n = 8).  Incubation of KN62 alone did 
not differ MLCK from control (n = 12 for control, n = 3 for KN62 
alone).  CCh-induced activity was not significantly varied 
between strips with and without Rho Kinase inhibition (n = 12 
for CCh, n = 8 for CCh with KN62 incubation).  Results are shown 
in Figure 42. 
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Figure 42. Effect of CaMKII inhibition on CCh-evoked MLCK 
activity. 
1 μM CCh-induced MLCK activities with and without Rho Kinase 
inhibition are presented.  Values expressed as percentage ± SEM 
of control MLCK activity.  Control, n = 12.  CCh-induced 
activity is 167% ± 21% of control (P < 0.05, n = 12).  CCh 
activity in the presence of 10 μM KN62 reduces CCh-induced 
activity to 140% ± 14% of control (P < 0.05, n = 8).   
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DISCUSSION 
Strip Generalities 
The strips obtained and studied were fairly consistent in 
their responses to carbachol and the kinase inhibitors used.  
Two distinct behavior patterns were noted – those with an early 
peak and moderate decay and those that displayed a slow rise of 
tension.  Strips of each subpopulation were appropriately 
utilized. It is important before the data is explored and 
interpreted to make a distinction between the behaviors of these 
muscle strips, and, for the most part, data from biochemical 
assays completed on isolated muscle cells.  Whereas the assays 
done in smooth muscle cells (particularly cultured cells) have 
as their samples uniform biochemical consistency and homogenous 
population, strips perform as functional tissue, with many 
different cell types.  These strips have cells bound to 
extracellular matrix, orienting the cells in an organized 
fashion and altering their functional abilities as a whole. 
These strips of tissue may have some connective tissue attached 
and certainly have attached the myenteric plexus which can alter 
both the response of the strips to agents and the composition of 
any homogenate, as compared to a homogenate of isolated muscle 
cells.  Differences in the possible amount of nerve tissue 
present or the tying/mounting of a particular strip could 
certainly affect the homogenate composition or the basic 
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contractile behavior of a given strip.  However, since each 
strip serves as its own control when performing comparisons to 
the effects of inhibitors/blockers, these differences in strip 
behavior/composition are minimized.   
Grand Means 
Since there is variance within the performance of strips under 
control conditions, mean values of the utilized metrics were 
studied.  The contractile response to carbachol of strips is 
concentration dependent as seen in Figure 11; there is some 
range of contractile values obtained.  This is primarily a 
consequence of the reporting of tension as grams and not as 
grams per gram of tissue.  Similar ranges of values are seen in 
the t = 1 min and t = 2 min values (Figure 12) and the area 
under the curve (AUC) values for the first, second, and first 
two minutes (Figure 13).  These ranges also could have been 
minimized through normalization by mass; nonetheless, the use of 
a given strip as its own control enables the appropriate use of 
the dependent t-test (repeated measurement dependence).  
Sizable, measured differences can be certified significant even 
if the range of data suggests otherwise.  Findings not found 
significant under these conditions can be viewed in the same 
manner – it is more likely that an effect is not present, than 
it is that significance was clouded by data variability. 
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Repeated Measures 
Once mounted, strips spend considerable time equilibrating in 
bath solutions.  This occurs following the initial mounting and 
immersion, as well as after washes to remove agonist or 
antagonist.  So that the effects of the long term presence of 
strips can be eliminated as a factor in any change in their 
behavior, measurements similar to those conducted in the 
presence of inhibitor were performed on strips incubated only in 
standard Krebs solution.  Figure 14 and Figure 15 demonstrate 
that after a 15 min incubation period, there is no significant 
effect on strip performance following incubation.  Any effects 
of incubation on strip behavior are consequences of the presence 
of inhibitor in the bath, not the fatigue/deterioration of the 
strip. 
Muscarinic Antagonism 
Both M2 and M3 receptors are prevalent in muscle tissue, and 
the literature shows a higher density of M2 receptors, but a 
greater functional role of M3 receptors [86].  Modulation of 
contraction by both types of receptors has been studied, with 
some studies asserting no necessary role of M2 or M3 receptors in 
smooth muscle contraction [84, 165].  Data displayed in Figure 
16 strengthens the idea that M3 receptor activity is critical for 
the contractile behavior that this study measures.  Blockade of 
M2 causes little effect in CCh-induced contraction; such 
 162 
contraction is abolished by M3 blockade.  Published data 
implicates M1 receptors in human colonic myenteric plexus [166].  
As these receptors are localized to nerves, neural contributions 
to observed contractile behaviors should be addressed. 
Effects of Neural Inhibition 
The effects of the attached plexus to strips may be the reason 
differences between strip behavior and isolated muscle cell 
behaviors are seen.  Such differences in isolated cell/intact 
strip behavior have been reported – the presence of nerve in the 
strip was the explanation for observed differences [10]. Nerves 
constitute a minor percentage of the mass of intact muscle, but 
in this preparation, the mass percentage of nerve tissue may no 
longer be trivial.  Tissue homogenates could have a substantial 
neural homogenate component.  Treatment of strips with TTX 
following control CCh contractions allows for this effect to be 
determined.  As shown in Figure 17, TTX incubation has no 
significant effect on the contractions induced by carbachol, 
although the data does trend to more contraction with TTX 
incubation.  Such a finding would not be in conflict with the 
literature – longitudinal muscle possesses innervation pathways 
populated with many inhibitory interneurons [11].  This 
inhibition could be relieved by TTX.  Figure 18 and Figure 19 
demonstrate similar effects of TTX on t = 1 min and t = 2 min 
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data, as well as on AUC values.  Again, AUC values did appear to 
trend higher, suggesting removal of inhibitory input by TTX. 
Kinase Inhibition Housekeeping 
The following table summarizes the findings of kinase 
inhibition on the contractile behavior of strips.  The tabular 
format allows for later comparisons between kinases to be made.  
Peak and AUC data are expressed as percentages of control ± SEM.  
Sample sizes can be found in the results section.  The reader is 
directed to Figures 22, 27, 33, and 39 in the results section 
for the percentage values of t = 1 min and t = 2 min 
experiments. 
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Table 1. Tabular representation of peak and AUC data for 
kinase inhibition experiments. 
Values represent percentage of control.  Sample sizes to be 
found in results section. Italics indicate P < 0.05, based on t-
test of original raw data.   
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Rho Kinase 
Inhibition 
ERK1/2 
Inhibition 
CaMKK/AMPK 
Ihibition 
CaMKII 
Inhibition 
Peak  
10 nM CCh 70 ± 13 60 ± 5 64 ± 7 70 ± 6 
1 μM CCh 62 ± 9 64 ± 6 67 ± 5 66 ± 6 
100 μM CCh 58 ± 8 65 ± 4 71 ± 7 51 ± 9 
AUC 0-1 min  
10 nM CCh 37 ± 5 60 ± 7 59 ± 4 65 ± 4 
1 μM CCh 33 ± 4 60 ± 6 73 ± 3 61 ± 9 
100 μM CCh 50 ± 8 65 ± 4 70 ± 9 62 ± 6 
AUC 1-2 min  
10 nM CCh 32 ± 4 60 ± 4 67 ± 6 67 ± 5 
1 μM CCh 37 ± 4 59 ± 9 74 ± 4 61 ± 9 
100 μM CCh 62 ± 12 55 ± 4 73 ± 7 72 ± 4 
AUC 0-2 min  
10 nM CCh 32 ± 6 64 ± 6 65 ± 3 69 ± 8 
1 μM CCh 37 ± 4 55 ± 4 74 ± 4 63 ± 8 
100 μM CCh 55 ± 8 61 ± 3 71 ± 7 67 ± 5 
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Effects of Rho Kinase Inhibition 
In this study, inhibition of Rho kinase led to significant 
decreases in basal tone (Figure 20), peak contraction (Figure 
21), contraction at 1 and 2 minutes post CCh administration 
(Figure 22), and AUC values (Figure 23).  Rho kinase is known to 
promote MLC20 phosphorylation (and contraction) through its 
phosphorylation of MYPT1, regulating contraction through 
inhibition of MLCP.  Rho kinase is also implicated in the 
activation of CPI-17, another MLCP inhibitor [73, 74, 167].  Rho 
kinase inhibition should have an obvious effect in promoting 
contraction, but its role seems more important in maintaining a 
sustained contraction, as its expression is heightened in tonic 
smooth muscle [112, 168].  Although Rho kinase inhibition shows 
decreases in tone as compared to control at t = 1 min, and t = 2 
min (Figure 22), when these data are viewed as percentages of 
the control contraction, it can be inferred that this sustained 
phase may not be appreciably reduced – the initial contraction 
was smaller, so contraction values at t = 1 min and t = 2 min 
are obviously reduced, and the “sustained phase” similar to 
control.  In this study, the more obvious finding is that Rho 
kinase is demonstrating an acute effect.  Peak contractions are 
reduced, at a similar level (slightly greater) than the other 
inhibitors. 
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The literature as a whole focuses upon Rho kinase as a 
modulator of sustained contraction.  Mbikou observed an acute 
effect of Rho kinase on contraction in airway smooth muscle, 
similar to findings of this study [169].  Frei found that the 
common Rho kinase inhibitor used in this study, Y27632, had no 
effect upon reducing CCh-induced contraction in colonic 
longitudinal muscle – the data of this study suggests a sizable 
effect [170].  The phosphorylation of MYTP1 and CPI-17 by Rho 
kinase can only aid in maintaining a level of tone; their 
inhibition (through Rho kinase inhibition) could not present 
itself as a decrease in induced contraction.  From the 
perspective of phosphatase inhibition via Rho kinase, incubation 
with Y27632 would increase basal phosphatase activity – MLC20 
phosphorylation would be decreased in resting state.  Here, 
Y27632 incubation causes a decrease in basal tone but a 
reduction of peak contraction.  Something else must be mediating 
this acute effect. 
Hagerty offers a mechanism whereby Rho kinase increases the 
activity of ZIP kinase, known to effect Ca
2+
-independent MLC20 
phosphorylation [99, 115]. This is supported by Ihara and 
MacDonald, who find direct phosphorylation of MLC20 by ZIP kinase 
as well as phosphorylation of MYPT1 by ZIP kinase, which is the 
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possible mechanism connecting Rho kinase to its phosphorylation 
actions on the protein MYPT1 [75, 171, 172]. 
Another possibility is direct phosphorylation of MLC20 by Rho 
kinase.  When Rho kinase is activated by Rho following M3 
activation, direct phosphorylation of MLC20 could take place.  
Inhibition of this possible phosphorylation mechanism would 
present itself as an acute effect.  Such phosphorylation of MLC20 
by Rho kinase has been reported [113].  The same group has 
implicated Rho kinase as an upstream mediator of a pathway that 
regulates nitric oxide production through eNOS in endothelial 
cells [114].  Although the muscle strips of this study possess 
no endothelial cells to generate NO, the nerves of the attached 
myenteric plexus are known to do so [11]. 
As compared to the other kinases, Rho kinase inhibition caused 
a far larger inhibition of all AUC values, and peak values 
except for those at the 10 nM CCh level.  This may indicate an 
acute effect as evidenced by the reduced peak contraction.  In 
addition, inhibition of the other kinases reduces the peak 
contraction by factor similar to their reduction in AUC values.  
Rho kinase inhibition causes far more reduction in AUC values as 
compared to its effect on the peak contraction.  Possibly a 
hybrid/combined effect exists. 
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Effects of ERK1/2 Inhibition 
Influence of ERK1/2 in smooth muscle contractile regulation is 
widely displayed in the literature.  ERK1/2 is reported to have 
a presence in pathways of pathophysiological smooth muscle, 
either through its ability to phosphorylate directly a pertinent 
substrate or by its transcription factor behavior [87, 118].  It 
has roles in desensitization pathways in gastric smooth muscle 
and mediates contraction in vascular smooth muscle through 
endothelin signaling [119, 162].  ERK1/2 signaling can also be 
increased by muscarinic activation in a manner that increases 
cPLA2, a critical enzyme in longitudinal muscle calcium handling 
[120].  Its activity seems to be connected to contraction; 
ERK1/2 inhibition reduces contraction in this study and others 
[172]. 
ERK1/2 inhibition in this study produces a reduction in both 
peak contractile values and AUC values (Figure 26 and Figure 
28).  The degree of inhibition is second only to Rho kinase.  
ERK1/2 inhibition caused predictable concomitant decrease in 
contraction at t = 1 min and t = 2 min (Figure 27), with similar 
percentage of peak profiles as control. With ERK1/2 
signaling/activity playing an established role in contractile 
regulation, its potential targets fall into several categories.  
Harnett verifies ERK1/2 phosphorylation of integrin-linked 
kinase (ILK) in esophagus, Muranyi links ILK to Ca
2+
-independent 
 170 
contraction via MYPT1 phosphorylation, and Deng offers direct 
phosphorylation of MLC20 by ILK [78, 81, 82].  Therefore ERK1/2 
can be connected to actions on MLC20 directly and through 
phosphatase inhibition.  Morrison from a biochemical standpoint 
and Klemke from a cell motility/proliferation angle both 
demonstrate that ERK1/2 directly phosphorylates MLCK and that 
this phosphorylation enhances MLCK activity [65, 66].  Others 
show similar effects that ERK1/2 can have modulatory effects on 
the MLCK as well.  Immunokinase assay data from this study 
suggests a possible enhancement by ERK1/2.  In addition to MLC20, 
MYPT1, and MLCK modulation, ERK1/2 is also known to 
phosphorylate accessory proteins in the contractile mechanism or 
cytoskeleton.  Both caldesmon and calponin are targeted by 
ERK1/2 [54, 117]. 
In conjunction with Rho kinase inhibition, ERK1/2 inhibition 
produced no additive reduction of contraction (Figure 29).  This 
can be considered either a consequence of their shared effects 
upon MYPT1 phosphorylation (which does speak more to sustained 
aspects) or that the inhibition of peak contraction by ERK1/2 
inhibition is mediated through its effects on direct 
phosphorylation of MLC20 via ILK, duplicated by the same actions 
through Rho kinase via ZIP kinase.  Yet, it is more likely that 
an additive effect should exist, considering all avenues of 
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inhibition that ERK1/2 possesses, and that careful 
experimentation would illuminate these. 
Effects of CaMKK/AMPK Inhibition 
AMPK has implications in cellular metabolism in cells/tissues 
with metabolic needs that may have large variations with 
activity, such as muscle.  Studies from tetanic electrical 
stimulation to hibernation to osmotic stress establish AMPK as a 
regulator/”switch” of glucose uptake, lipid metabolism, and 
mitochondrial manipulation [135, 142, 173].  CaMKK is an 
upstream effector of AMPK activity, with the beta isoform of 
CaMKK as the particular modulating kinase [134, 139].  This 
regulation of AMPK can be mediated through M3 activation [136]. 
However, the upstream regulation of AMPK by CaMKK is time 
dependent.  After sustained activation of AMPK by CaMKK, 
blockade of CaMKK no longer can affect AMPK activity in a model 
of tetanic contraction [174].  In addition, the alpha isoform of 
CaMKK does not modulate AMPK activity as it relates to metabolic 
processes [138].  The inhibitor used in this study (STO-609) 
targets both isoforms of CaMKK for inhibition, so use of this 
inhibitor does have consequences beyond AMPK [140, 141]. 
As a regulator of contraction, both Horman and Al-Shboul have 
shown that AMPK activity leads to phosphorylation of MLCK kinase 
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in a manner that reduces its ability to foster contraction [143, 
175].  Bultot demonstrates that AMPK can directly phosphorylate 
MLC20, but that such is unlikely to be its proper physiological 
function [144].  In this study, inhibition of CaMKK activity was 
found to reduce peak contraction and AUC values (Figure 32 and 
Figure 34).  CaMKK inhibition caused predictable concomitant 
decrease in contraction at t = 1 min and t = 2 min (Figure 33), 
with similar percentage of peak profiles to control.  MLCK 
activity was also decreased with CaMKK inhibition (Figure 36).  
Also, additive effects of CaMKK inhibition with Rho kinase 
inhibition were observed, implicating CaMKK effects on the 
kinase side of MLC20 phosphorylation regulation (Figure 35).  
These data are in conflict with Al-Shboul and Horman.  Al-
Shboul, however, made his findings in isolated circular muscle 
cells (no neural input) and Horman in chicken gizzard, a 
muscular structure with smooth muscle and innervation but little 
similarity to longitudinal muscle in gut.  The findings of this 
study are in a model of different muscle type and are from 
strips, which may contract with different regulation than 
isolated cells (Al-Shboul) or have a different neural 
contribution as a homogenate for MLCK assay (Horman). 
Furthermore, studies by Donsmark and Blair show that AMPK 
activity increases with electrically stimulated contraction 
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[176, 177].  It is conceivable that AMPK activity increases as a 
consequence of contraction, not as a modulator of contraction, 
but to evoke the metabolic modulatory effects in tissue whose 
metabolic needs have been advanced.  The current study also used 
an inhibitor (STO-609) which does not discriminate between the 
alpha and beta isoforms.  Only the beta isoform is an effector 
of AMPK, and any independent effects CaMKK may have on 
contraction would be simultaneously affected.  Schmitt shows 
ERK1/2 activation by CaMKK via calcium-calmodulin dependent 
kinase I (CaMKI), and this study has established the importance 
of ERK1/2 signaling in longitudinal muscle.  CaMKK inhibition 
would affect this negatively [178].  Lastly, like CaMKII, this 
enzyme is dependent on calcium-calmodulin interactions for 
regulation of its activity, and with the unique calcium handling 
of longitudinal muscle, could conceivably have different effects 
as a result of different calcium dynamics.   
Effects of CaMKII Inhibition 
In this study, CaMKII inhibition by KN62 incubation caused 
decreases in basal tone (Figure 37), peak tension development 
(Figure 38), and AUC values (Figure 40). CaMKII inhibition 
caused predictable concomitant decrease in contraction at t = 1 
min and t = 2 min (Figure 39), with similar percentage of peak 
profiles to control.  CaMKII inhibition resulted in a decrease 
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of CCh-induced MLCK activity (Figure 42).  These data are in 
conflict with Murthy, who found that CaMKII inhibition reduced 
MLCK activity and Tansey who found KN62 causes a decrease in 
calcium sensitization of MLCK, reducing its activity [84, 129].  
Both of these studies were in isolated cells of muscle types 
(circular muscle, tracheal muscle) who differ in characteristics 
from longitudinal muscle.  Hashimoto found that CaMKII can 
phosphorylate MLCK as a negative effector (in conflict the 
presented data), but that such phosphorylation could only occur 
before binding of calcium-calmodulin to MLCK [130].  As with 
CaMKK, differences in calcium handling in longitudinal muscle 
might preclude this effect, and the Hashimoto experiment was 
performed with purified protein (both MLCK and CaMKII).  The 
additive effects of CaMKII inhibition with Rho kinase inhibition 
(Figure 41) suggests effects of CaMKII exist on kinase leg of 
regulation. 
Studies by Henning and Pauly expose CaMKII as critical in the 
processes of migration and hypertrophy, where positive 
associations with myosin are more often observed than 
associations that decrease activity or important cooperative 
binding [125, 126].  Edelman and Kim demonstrate direct 
phosphorylation of MLC20 with CaMKII activation, which would 
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agree with the findings of decreased basal tone with incubation 
of CaMKII inhibitor (Figure 37) [132, 179].   
CaMKII also has modulatory effects on ion channels and SR 
which would present heightened importance given the calcium 
handling modality of longitudinal muscle.  McCarron implicates 
CaMKII in calcium channel regulation as a possible feed-forward 
mechanism, increasing calcium influx with CaMKII activity [180].  
Greenwood shows that regulation of ion channels by CaMKII can 
differ between arterial and venous smooth cells [121].  It 
remains conceivable that calcium channel regulation could be 
different in longitudinal muscle (versus circular) where such 
effects would have larger consequences on calcium mobilization. 
Moreover, CaMKII can modulate SR receptors.  Witcher finds 
that CaMKII phosphorylation of cardiac ryanodine receptors leads 
to enhanced calcium release.  This effect is not seen in 
skeletal muscle [127].  Given the similarities of calcium 
handling in cardiac and gut longitudinal muscle, such inhibition 
of CaMKII would reduce calcium mobilization and contractile 
activity, as findings in this study demonstrate.  Lastly, CaMKII 
is an obvious upstream effector of ERK1/2.  Marganski shows an 
essential role of CaMKII in regulation of downstream ERK1/2 
activity [124].  ERK1/2 importance in contractile regulation in 
colonic longitudinal muscle has been established by the current 
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findings.  Blockade of CaMKII would affect contraction in a 
manner similar to ERK1/2 regulation, and this is in concert with 
these data. 
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Putative Longitudinal Model 
Because the contrary effects of CaMKK and CaMKII inhibition as 
compared to the circular muscle model (Figure 2), an updated 
model is offered for longitudinal muscle.  The effects of CaMKK 
and CaMKII upon ERK1/2 activation, ion channels, SR receptors, 
and MLC20 phosphorylation have been added.  The new model is 
offered in Figure 43, and both models together in Figure 44. 
  
 178 
 
  
Figure 43. Model for Longitudinal Muscle Regulation. 
Open Triangles indicate legacies of putative circular model 
roles of CaMKK/AMPK and CaMKII.  Arrows indicate positive 
regulation. 
 179 
 
  
 180 
 
  
Figure 44. Circular and Longitudinal Muscle Regulation by 
Kinases. 
Top Panel: Putative circular muscle model. 
Bottom Panel: Putative longitudinal muscle model. Open 
triangles indicate contrary legacies from circular model. 
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Avenues to Explore 
To further and strengthen the model, the following experiments 
are proposed: 
 Western Blot analysis to observe MLC20 phosphorylation 
levels directly under control conditions and in response to 
CCh, with and without kinase inhibition. 
 Kinase assays for these candidate kinase, as well as ZIPK 
and ILK.  These assays could offer information regarding 
Ca
2+
-independent contraction regulation, and with 
appropriate use of inhibitors could sequence any possible 
cascades. 
 Exploration of phosphatase activity by these kinases.  This 
could be accomplished indirectly through observation of 
phosphorylation/activation of phosphatase inhibitors MYPT1 
and CPI-17 
 Experiments with kinase inhibition in conjunction with 
muscarinic antagonism and Na
+
 channel blockade via TTX, to 
determine neural contributions and possible modulation by M2 
signaling. 
 Combination of kinase inhibition on contraction to 
determine possible additive effects or redundancies. 
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